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· By 2005, an estimated 500 000 people with HIV had initiated highly 
active antiretroviral therapy (HAART) in sub-Saharan Africa. However, 
disproportionately more women than men have accessed HAART in most 
developing countries including South Africa. While there has been considerable 
recent interest in the determinants of mortality among patients receiving HAART 
in developing countries, there is conflicting evidence about gender differences and 
survival in HAAR T programmes. 
This study explored whether there were gender differences in early 
mortality among 2 843 treatment-naive men and women entering care in a large 
South African HAART programme. The study was a secondary analysis of patient 
records covering three time periods: person-time from programme entry to the 
initiation ofHAART; person-time from HAART initiation to one year on 
treatment; and the total person-time from programme entry to one year on 
HAART. Cox' s proportional hazards regression ·was used to investigate crude and 
adjusted associations between basehne characteristics and mortality as we11 as 
loss-to-follow-up (LTFU). Using the Sobel test, the study explored whether the 
degree of disease ( according to CD4 count and WHO stage) played a mediating 
role in any association between gender and mortality. 
In all three time periods, the analysis found a strong crude associ~tiol). 
between male gender and mortality. Prior to HAART-initiation, there was a 31 % 
increase in the risk of mortality (crude Hazard Ratio (HR) 1.31, 95% CI, 0.93-
1.86; p=0.131). In the period on HAART, this association strengthened (crude 
HR 1.57, 95% CI, 1.14-2.16; p=0.005). Overall, male gender increased the risk of 
mortality in the total cohort by 49% (crude HR, 1.49, 95% CI, 1.17-1.88; p=OOl). 
Adjustment for baseline characteristics, including CD4 count and WHO 
stage, attenuated these crude associations. After adjustment, there was no increase 
in risk associated with male gender in the period pre-HAART (HR 1.01, 95% CI, 
0.67-1.51). On HAART, there was a 19% increase in risk (HR 1.19, 95% CI, 
0.88-1.67). In the total cohort, this was slightly attenuated (HR 1.15, 95% CI, 
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0.93-1.50). There was evidence of mediation by degree of disease. In the pre-
HAART period, the Sobel test found significant associations between mortality 
and CD4 count (p=0.044) as well as WHO stage (p=0.003). On HAART, too, 
CD4 count (p=0.045) and WHO stage (p<0.001) appeared to mediate the effect of 
gender on death. Similarly, in the total cohort, there was evidence to support 
mediation by CD4 count (p=0.035) and WHO stage (p<0.001). 
There was a crude association between male gender and the risk of being 
L TFU (HR for L TFU during the total study period comparing males to females, 
1.26, 95% CI, 0.89-1.78; p=0.194). This was strengthened by adjustment for age 
and monthly income (HR,1.35, 95% CI, 0.92-1.97). 
In this cohort, men appeared to have worse survival prospects than women 
due to more advanced HIV disease on programme entry. Previous studies have 
attributed the disproportionate access of women to HAART to gender differences 
in health seeking behaviour. This study argues that the prime obstacle might be 
the existing orientation of primary health care systems in developing countries 
towards the needs of women more than those of men. It suggests that women have 
better access to primary health services through the existing focus on maternal and 
child health. Women who are diagnosed and referred for HAART through these 
services are generally younger and healthier than men, who are diagnosed through 
services for tuberculosis (TB) and sexually transmitted infections (STis). This 
might explain why fewer men than women access HAART, and why they are 
diagnosed at later stages of disease progression. As a result, men may be 
disadvantaged in access to HAAR T in South Africa. 
The study suggests a number of short- and long-term solutions including: 
. fu_rtli~r rese~rch pn ob~tacl~s to m~l~ acc;e~s to HAAR T.; changes in pation~l 
policy; and the establishment of male-friendly services as an entry point for men 
into broader health services. Such approaches might facilitate the earlier diagnosis 
and treatment of men and improve their survival in HAART programmes. 
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1 INTRODUCTION 
The HIV/ AIDS pandemic continues to grow. A recent report from UN AIDS 
and the World Health Organisation estimates that there are over 33 million people 
worldwide living with HIV (UNAIDS/WHO, 2007). Sub-Saharan Africa is the 
worst-hit region with 22.5 million adults and children living with HIV and an 
estimated 1.6 million adult and child deaths due to AIDS (UNAIDS/WHO, 2007). 
Women are disproportionately affected by HIV infection, both in living with 
infection and in acting as caregivers for infected family members. In sub-Saharan 
Africa, the majority of people living with HIV infection are women, and the figure 
has risen steadily since 1990. 
Southern Africa remains at the centre of the pandemic: 35% of all people 
infected with HIV live, and 32% of AIDS deaths worldwide occur, in the region 
(UNAIDS/WHO, 2007). South Africa has one of the world' s worst epidemics. In 
1995, national HIV prevalence was estimated at 4.5%, increasing to 9.9% by 
1998. By 2006, the country had the largest number of people living with HIV 
infection in the world. National prevalence was estimated at 11 . 8%. Prevalence 
among women was higher than among men (12.7% vs 10.2%), amounting to 
nearly 5 .4 million South African adults and children infected with HIV (Harris et 
al. , 2007). The scale of the HIV/AIDS epidemic in South Africa has a massive 
impact on both individual and population health. The burden of opportunistic 
infections is growing, mortality is increasing, and life expectancy is dropping. By 
2010, it is estimated that life expectancy may fall below 40 years of age 
(Anderson and Van Rensburg, 2006). 
The advent of highly active antiretroviral therapy (HAAR T) in 1996 
transformed the prognosis for people living with HIV/AIDS. Until then, only 
single or dual therapy was available, and drug resistance developed fairly quickly. 
With HAART, HIV became a chronic managed disease for those who could 
afford the treatment. Until fairly recently, HAART was unaffordable to most 
people living with HIV in developing countries. Over the past few years, however, 
access to HAART has been expanded dramatically. In 2005, there were an 
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estimated 500 000 people on HAART in sub-Saharan Africa (Bekker et al. , 2006), 
the majority of whom were women (UNAIDS/WHO, 2007). Prior to the 
widespread availability ofHAART, the median survival in Africa after an AIDS 
diagnosis was less than one year (Rosen et al. , 2007). As treatment is only 
initiated after an AIDS diagnosis for most Africans living with HIV, most of those 
who started treatment would have died within a year without treatment. The 
individual and public health benefits of this reduced morbidity and delayed 
mortality are enormous. 
In developing countries there are now large cohorts of people on HAAR T, 
with high-quality data on clinical and immunological outcomes. Several studies 
(Lawn et al. , 2006a, Bekker et al., 2006, Etard et al. , 2006, Stringer et al. , 2006) 
have found an increased risk of mortality within the first 4-6 months of entering 
HAART programmes in developing countries. From six months, however, 
clinical, virological and immunological responses to HAART in developing 
countries compare favourably with those in developed countries (Coetzee et al., 
2004, Braitstein et al. , 2006, Bekker et al. , 2006, Stringer et al. , 2006, Ferradini et 
al. , 2006). This provides a valuable opportunity to explore differences within 
fairly homogeneous and representative populations. However, there has been little 
analysis of the impact of gender on mortality in HAART programmes. 
At first, research on these programmes focused largely on comparing 
outcomes in developing and developed countries. As the HAART programmes 
matured, issues of sustainability and patient retention came to the fore . This 
shifted the focus of research to issues such as: how effective are the services, how 
can they be rolled out to reach the largest numbers, how to cope with co-infections 
such as TB, and what are the gaps in service delivery. 
One such gap appears to be the late diagnosis and initiation of treatment for 
men. HIV/AIDS is commonly known as a gendered epidemic because of the 
perceived triple burden borne by women: in addition to living with HIV infection, 
women also care for sick family members and are often the primary breadwinners 
in households (National Department of Health, 2004a). In South Africa, women 
- 13 -
account for 55% of the HIV-positive adults overall, and in certain age groups, the 
proportion is even greater (National Department of Health, 2004a). The 
prevalence in young adults (15-24 years) is 3.7% for males and 16.9% for females 
(Harris et al. , 2007). Among those aged 25-29 years, the prevalence is 33.3% 
among women and 12.1 % for men. However, uptake of HAART in three South 
African provinces has been 75% female and 25% male (Schneider et al. , 2007). At 
the Johannesburg General Hospital, twice as many women as men accessed 
HAART (Hudspeth, 2004). The situation appears to be the same in the private 
sector. In one large workplace programme, for example, 60.5% of those accessing 
HAART were female although women only comprise 33% of the formal 
workforce (Nachega J, 2006). 
Reasons for the low uptake ofHAART services by men have not been fully 
explored, and the evidence is mixed. It seems likely that gender differences in 
health seeking behaviour play a part. However, there appears to be a broader 
issue: men' s limited access to general health services. The 1998 Demographic and 
Health Survey (Department of Health and Medical Research Council, 1998) 
reported that across all race groups and geographic areas, significantly more 
women than men accessed public health services. 
In view of the massive scale-up of HAART, it is important to understand 
potential gender differences in the progression of HIV and in access and responses 
to HAART. This dissertation uses the term 'gender' to include both sex and 
gender ctifferences between men and women. Historically, sex was regarded as the 
biology of being male or female, while gender described socially constructed roles 
for men and women in a given society. Towards the end of the 20th century, 
feminist theory developed terminology for gender issues. By 1980, there was 
consensus among most feminist writers that ' gender' would only be used for traits 
that were socioculturally adapted and would not include biological differences 
(Phillips, 2005). However, some writers (Phillips, 2005, Diamond, 1995) argue 
that it is not possible to assess the impact of sex or gender on health independently 
of each other. They note the strong interaction between gender and biology in 
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every setting. Phillips (Phillips, 2005), for example, argues for a broader use of 
gender ' as the composite of both social and biological health effects associated 
with being either male or female' . She suggests that by doing this, researchers 
may be able to study the true effects without 'getting stuck at enumerating sex 
differences'. In this dissertation, the term 'gender' has been used to describe 
issues of both sex and gender. 
This analysis explores one aspect of the gendered epidemic: the comparative 
survival of men and women in a South African HAART programme. HAART 
was initially only available to patients in the public sector through research sites 
and a pilot project run by Medecins sans Frontieres from 2001. In 2004, 
government reluctantly began offering HAART through the public health system. 
Due to resource constraints, treatment was only available to individuals with 
advanced disease. By April 2007, the International Treatment Preparedness 
Coalition (ITPC) estimated that about 260 000 people were receiving HAART in 
the public sector and an estimated 31 000 were on official waiting lists 
(lnternational Treatment Preparedness Coalition, 2006). However, ITPC estimated 
that over 625 000 people in South Africa still urgently required HAART. 
In the early days ofHAART, there was concern that men would have better 
access to HAART due to existing gender imbalances (Nattrass, 2006). In fact, it 
appears that women have better access to HAART in many developing countries 
(Muula et al. , 2007). In addition, there is some evidence to suggest that women 
may survive better than men in HAART programmes (Ferradini et al., 2006). 
However, few analyses from developing countries have examined the potential 
role of gender in influencing outcomes on HAART. 
If it is true that women have better comparative survival rates, this may be 
due to biological, social and/or structural factors, or due to degree of disease at 
initiation ofHAART. The possibility of mediation by degree of disease is 
especially plausible, as numerous studies have found CD4 cell count at baseline to 
be a risk factor for mortality on HAAR T. In Zambia, for example, a study of over 
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16 0000 individuals found a strong association between mortality and advanced 
disease stage at baseline (Stringer et al. , 2006). 
It is possible that women may do better on HAART simply because they are 
diagnosed and initiate HAART earlier in the course of disease. Certainly, public 
health services in much of sub-Saharan Africa, and particularly South Africa, are 
oriented more towards the health needs of women than men, with a strong focus 
on maternal and child health. As a result, more women use the public health 
services, more women access voluntary counselling and HIV testing, often during 
pregnancy (Lawn et al. , 2006a), and more women than men are on HAART 
(Bekker et al. , 2006). If men are being diagnosed and started on treatment at a 
later stage of disease, it is possible that degree of disease is mediating the apparent 
association between gender and the risk of mortality in a HAART programme. 
This analysis explores whether there is a difference in the survival of men 
and women in a large South African HAART programme. If such a difference is 
present, the analysis will assess whether this association is explained by degree of 
disease. If mediation is found, the study will explore reasons why men are 
accessing HAART later than women, and suggest some possible solutions to 
address any gender disparities in access to HAAR T. 
- 16 -
2 AIM 
The aim of this analysis is to explore the association between gender and 
death from programme entry to a year on HAAR T, among treatment-nai:ve 
individuals entering a government antiretroviral therapy programme. To achieve 
this, the study objectives are: 
2.1 To describe the demographic and clinical characteristics of the study 
cohort; 
2.2 To examine overall survival and loss-to-follow-up (LTFU) in the 
programme, making distinctions between person-time pre-HAART, 
person-time on-HAART and total person-time; 
2.3 To identify crude associations between gender, other baseline participant 
characteristics and the occurrence of death in each time period. Of the 
characteristics of interest include age, viral load, CD4 cell count, WHO 
stage, haemoglobin and income~ 
2.4 To investigate how the association between gender and mortality during 
each of the three time periods changes after adjustment for other 
participant characteristics; 
2.5 To assess whether degree of disease (as measured by viral load, CD4 cell 
count and/or WHO stage) mediates any association between gender and 
death; 
2.6 To identify crude associations between gender, other baseline participant 
characteristics and the occurrence of L TFU in the time period on HAAR T 
and the total time period; 
2. 7 To identify how the association between gender and LTFU changes in the 
time period on HAAR T and the total time period after adjustment for other 
participant characteristics. 
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3 LITERATURE REVIEW 
A search of the electronic database Medline using the PubMed interface 
(National Library of Medicine, Bethesda, MD) was conducted to review the 
literature on HIV/AIDS, sex/gender and HAART, and access to HAART. Search 
terms included: 'gender and HIV/ AIDS', 'sex natural progression HIV', 
'HAART', 'biologic differences and HAART', 'mortality pre-HAART and on-
HAAR T', ' gender and health seeking behaviour', 'gender and access to health 
services', 'barriers to health care', 'utilisation of health services in South Africa' . 
The search reviewed studies in developed as well as developing countries, but 
only included publications in English. The literature review included studies on 
mortality among HIV-infected individuals immediately prior to, and/or during, 
HAART. 
3.1 HIV epidemiology 
It is estimated that there are over 33 million people worldwide living with 
HIV (UNAIDS/WHO, 2007). Nearly two-thirds of these people (22.5 million 
adults and children) live in sub-Saharan Africa, where the epidemics are different 
in scale and trends. Southern Africa is the most seriously affected region, home to 
over one-third of all people living with HIV. South Africa is the epicentre of HIV, 
with the highest prevalence in the world (UNAIDS/WHO, 2007). It appears that 
the rapid spread of HIV in the country has been fuelled by a legacy of social 
inequality, poverty, mobile populations, high levels of sexual violence, disrupted 
family structures and weak leadership (National Department of Health, 2004a). 
In South Africa, as in many other developing countries, women are 
disproportionately affected by HIV/ AIDS. In 2006, national prevalence was 
estimated at 11.4%: among women, prevalence was 12.7% compared with 10.2% 
among men (Harris et al., 2007). Nearly 55% of HIV-positive adults are female 
(National Department of Health, 2004a, SANAC, 2007) and within certain age 
groups, there is a startling gender disparity. In young adults, an overall prevalence 
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(15-24 years) of 10.4% masks the difference between 3.7% for males and 16.9% 
for females (Harris et al. , 2007). This disparity persists at older ages. In the age 
group 20-24 years, there is 23 .9% prevalence among women and 6.0% among 
men. Similarly, among those aged 25-29 years, the prevalence is 33.3% among 
women and 12.1 % for men. Women in the age group 25-29 are the worst affected 
with prevalence rates of up to 40% (Harris et al. , 2007). 
Women appear to be at higher risk of HIV acquisition than men due to 
biological and social reasons. Possible biological mechanisms include: immature 
genital tracts in young women, increased area for surface contact in the vagina, 
high rates of undetected sexually transmitted infections (STis), and the fact that 
the vagina retains fluids for a comparatively long time (National Department of 
Health, 2004a). Social reasons include the often marginalised status of women and 
constraints on their participation in the economic, social, and political life of a 
country. Generally, women experience discrimination on the basis of class, race 
and gender (National Department of Health, 2004a, SANAC, 2007). Economic 
dependence on men can restrict women' s ability to protect themselves from HIV 
infection. High levels of violence against, and abuse of, women also contribute to 
their vulnerability. 
3.2 Natural history of HIV 
HIV ( the human immunodeficiency virus) is a retrovirus that infects the 
human immune system and undermines its functioning. Initially there is a brief 
period of sub-clinical infection, often unnoticed by the infected individual. 
Thereafter, HIV can remain latent and asymptomatic for up to 10 years. Over time 
the immune system weakens, causing increased susceptibility to opportunistic 
infections. Symptoms of early symptomatic disease include fever, diarrhoea, 
recurrent herpes simplex infections and unexplained weight loss. An AIDS 
diagnosis is made once the CD4 cell count drops below 200 cells/µL and/or the 
individual has one or more AIDS-defining illnesses (National Department of 
Health, 2004a). 
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Before the advent ofHAART, there were high levels of morbidity and 
mortaJity once individuaJs had progressed to AIDS. This pattern was found in 
both developed and developing countries. Pre-HAART, median survival from 
seroconversion to death in Africa was approximately 10 years. This was about a 
year less than the median survival time to death in developed countries pre-
HAART (Morgan et al., 2002). 
3.3 HIV/AIDS & HAART 
The advent of highly active antiretroviral therapy (HAART) in 1996 
transformed the prognosis for people living with HIV/AIDS. Previously the only 
treatment was single or dual therapy for a limited period, after which drug 
resistance would develop. For individuals who could afford the prohibitively 
expensive triple therapy, HIV/AIDS became a chronic managed disease. Egger 
(Egger et al. , 1997) prospectively followed 5176 Swiss patients with HIV who 
started HAAR T. Depending on the year of enrolment into the cohort, the risk of 
mortality was reduced by 19% - 62% and the risk of progression to AIDS was 
reduced by 18% - 73%. More recently, the CASCADE collaboration pooled data 
from 22 European cohorts and confirmed that HAAR T decreased overall and 
cause-specific mortality (Smit et al. , 2006). 
In developing countries, too, there are now large cohorts of people on 
HAART with good quality data. After six months on treatment, clinical, 
virological and immunological responses in developing countries compare 
favourably with those in developed countries (Marins et al. , 2003, Coetzee et al. , 
2004, Braitstein et al. , 2006, Bekker et al. , 2006, Stringer et al., 2006, Zachariah et 
al. , 2006). Ferradini (Ferradini et al. , 2006) found that even in a large-scale 
programme in Malawi with simplified HAART regimens and few medical and 
monitoring resources, outcomes were comparable with those in developed 
countries. 
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Although the overall outcomes are good, numerous studies report high early 
mortality rates among patients entering HAAR T programmes in developing 
countries (Etard et al., 2006, Bekker et al., 2006, Stringer et al., 2006, Braitstein et 
al., 2006). A comprehensive review of mortality rates in adults on HAART in sub-
Saharan Africa found that 9% - 26% of patients die within their first year on 
HAART, the majority in the first few months (Lawn et al., 2006a). A comparison 
of mortality rates in the first year on HAART in high- and low-income countries 
found that the adjusted hazard ratio of mortality (low-income vs high-income 
settings) dropped from 4.31 (95% CI, 1.57-11.81) during the first month to 1.5 
(0 .70-3.01) in the last 5 months of the analysis (Braitstein et al., 2006). 
These extremely high rates of early mortality appear to be largely due to 
delays in diagnosis and initiation ofHAART (Lawn et al., 2006a). In a recent 
study, Fairall and colleagues followed 4 570 patients in a South African public 
sector HAART programme (Fairall et al., 2008). After a year, more than half 
(53 .2%) had died. Of those patients who had died, 87% had not received HAART. 
This is probably due to strict criteria for initiating therapy in resource-constrained 
settings. As a result, many patients starting HAART in poorer countries have 
advanced disease, and are suffering from co-infections including tuberculosis and 
invasive infections (Braitstein et al., 2006). These patients have limited - if any -
access to comprehensive HIV management and care, and it is highly likely that 
they would be sicker than patients starting HAART in richer countries. This 
confirms the need to diagnose and initiate treatment at earlier stages of disease, 
and to understand any gender differences in access and response to HAAR T. 
3.3.1 Gender and survival on HAART 
Although it is biologically plausible that women and men may progress and 
survive differently on HAAR T, there does not appear to be any consensus on the 
issue. Numerous studies have confirmed low CD4 cell count at baseline as the 
strongest predictor of early mortality on HAART (Hogg et al., 2001, Egger et al., 
2002, Lawn et al., 2006a). There is some evidence to suggest that CD4 cell counts 
may differ by gender, with or without HIV. For example, an early study to 
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establish reference ranges for CD4 cell counts in HIV-negative women and men 
found that the absolute CD4 cell counts were higher in women than in men (Maini 
et al., 1996). Some years later, Prins and colleagues (Prins et al., 1999) found that 
prior to the advent of HAAR T, women seroconverted, progressed to AIDS and 
died at higher CD4 cell counts than men did. Giordano (Giordano et al. , 2003) 
found that on HAART, the CD4 cell response of women was greater than that of 
men, even after adjusting for baseline disease parameters. They suggested that this 
was probably due to pharmacokinetic differences but might also be due to women 
repopulating CD4 cells in response to virus suppression faster than men. 
Viral loads may also differ between men and women. For example, Sterling 
and colleagues (Sterling et al. , 2005) found that at given CD4 cell counts, average 
viral loads were lower in women than in men. The underlying mechanisms for 
differences in viral dynamics have not been established but may include hormonal 
influences such as sexual maturation, the menstrual cycle, hormonal 
contraception, hormonal replacement therapy and pregnancy. 
If it is true that viral dynamics are different between men and women, their 
responses to treatment may also be different. On the basis of this, Finkel (Finkel et 
al., 2003) studied patients who had achieved sustained virological suppression on 
HAART. They found that women in this group had a greater immunological 
response to therapy than men and suggested that this may be due to significant 
pathological differences between men and women. Similarly, in a study of 2620 
patients on HAART, Collazos (Collazos et al. , 2007) found that women had better 
clinical and viro-immunological responses to HAART than men, even after 
adjusting for other variables. The authors concluded that gender played a small 
but significant role in clinical and laboratory outcomes of HIV infection. In 
contrast, a recent systematic review (Nicastri et al ., 2007) found little evidence 
that gender influenced responses to HAART. The authors noted, however, that 
most of these studies may have had insutli.cient power to detect true gender 
differences. 
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If gender does influence responses to treatment, it is important to understand 
how it impacts on survival in HAART services. There are now large HAART 
programmes in developing countries which are being accessed predominantly by 
women. In the early days ofHAART, there was concern that men would have 
better access than women due to existing gender inequities (Nattrass, 2006). In 
fact, women appear to have disproportionately better access than men in 
developing countries (Muula et al., 2007). However, there has been little in-depth 
analysis of the impact of gender on mortality in HAAR T programmes. The studies 
that have been undertaken have produced mixed results. 
Two studies from Brazil found that women were at higher risk of mortality 
on HAART than men. An early study (Santoro-Lopes et al., 1998) found that after 
adjusting for age, AIDS-defining conditions and baseline CD4, the risk of 
mortality in women was more than three times the risk in men (adjusted HR 3.33; 
p=0.170). In a subsequent retrospective cohort study of university out-patient 
attendees, Braga and colleagues (Braga et al., 2007) found a slight increase in risk 
among women compared with men (crude HR 1.22), which strengthened when 
adjusted for a number of baseline factors (adjusted HR 1.86; 95% CI, 1.14-3.03 ; 
p=0.020). 
Conversely, a number of African studies found that male gender was an 
independent predictor of death in the first six months on HAART (Ferradini et al., 
2006, Lawn et al., 2006a, Stringer et al., 2006). Lawn (Lawn et al., 2006a) found 
that in the first four months of treatment, men had nearly double the relative 
hazard of death of women (HR 2.00; 95% CI, 1.10-3.62). In rural Malawi, after 
adjusting for numerous baseline factors, Ferradini (Ferradini et al., 2006) found 
that in the first six months ofHAART, men had nearly twice the crude risk of 
death of women (HR I . 76; 95% CI, 1.29-2.39). After this period, and after 
adjusting for BMI and CD4 cell count at baseline, the risk for men was slightly 
attenuated, but still significantly higher than for women (HR 1.63, 95% CI, 1.15-
2.31). The authors suggested that this could be due to confounding factors that 
had not been identified. 
- 23 -
Finally, numerous studies found no evidence of gender-based differences in 
survival on HAART (Hacker et al ., 2004, Nicastri et al ., 2005, Hogg et al. , 2001 , 
Seyler et al. , 2003, Weidle et al., 2002). A collaborative analysis of 13 cohort 
studies found that despite gender differences in responses to treatment, there was 
no difference in the prognosis of men and women (Egger et al. , 2002). In Brazil, 
Hacker (Hacker et al., 2004) found that the large differences in male and female 
death-to-case ratios that were present pre-HAART had mostly disappeared in a 
few years. Jn a large national roll-out programme in Zambia, Stringer and 
associates (Stringer et al., 2006) also found that an apparent association between 
male gender and mortality (crude HR 1.40; 95% CI, 1.20-1.60) was attenuated 
after adjustment for baseline factors (HR 1.20; 95% CI, 0. 90-1 .50). 
These conflicting results led to two reviews on the issue. One review 
comparing low and high-income countries found no significant association 
between gender and progression rates on HAART (Braitstein et al. , 2006). 
Similarly, a systematic review of published studies on gender and HAART found 
little evidence of differences in the survival of women and men on HAAR T 
(Nicastri et al. , 2007). 
Although there is little consensus on gender differences in responses to 
HAART, there is more substantial evidence that gender disparities in access to 
HAART could impact on outcomes. This seems to be due to a range of social and 
structural factors, which differ depending on the context. 
3.4 Gender & access to health services 
Women and men appear to access health care services differently (Govender 
and Penn-Kekana, 2007). These disparities manifest differently in developed and 
developing countries, and might be a reflection of inequities in health systems 
rather than individual health seeking behaviour. 
In developed countries, women appear to be disadvantaged in access to 
health care (Bhalotra et al., 2007, Gebo et al. , 2005). Often poor and marginalised, 
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they juggle the needs of their children and other dependants with their own needs, 
often at the cost of their health. Obstacles to health access for women include their 
marginalised social status, low socio-economic status (SES) and attitudes of 
health care providers (Bertakis et al. , 2000). For example, an American study 
early in the epidemic found that HIV-infected women were at increased risk of 
death (Melnick et al. , 1994 ). The authors ascribed this to differential access to 
health services and the low socio-economic status of women. These disparities 
can be seen in other areas of health. Bhalotra (Bhalotra et al ., 2007) describes, for 
instance, how gender disparities in access to health services lead to poor health 
outcomes in coronary heart disease (CHD) treatment. Following the natural 
history of CHD, the authors found gender differences at every stage: risk 
management, screening, diagnosis, treatment and rehabilitation. Women had more 
risk factors and were less likely to receive lifesaving treatment. Similarly, a recent 
study in Sweden found that men presenting with skin diseases at an outpatient 
clinic received better treatment than women (Osika et al. , 2005). 
These differences persist in access to HAAR T. Data from the first years of 
HAART in the United States of America showed that men were more likely to 
receive HAART than women (Smith and Kirking, 1999, Andersen et al. , 2000). In 
more recent years, the situation appears unchanged. A recent study of 10 905 
Americans with HN confirmed that males were still more likely to receive 
HAART than women (Gebo et al. , 2005). 
In contrast, women in developing countries are generally reported to be 
better users of primary health care (PHC) services (Govender and Penn-Kekana, 
2007), although there is limited and sometimes only anecdotal evidence to support 
this. This appears to fly in the face of explanations for women' s limited access to 
health in richer countries. Why do women in poorer countries, despite inequities 
in power, social and economic status (Braitstein et al. , 2008a), often have better 
access to health services? 
The reasons do not appear to have been rigorously explored. Differences in 
health seeking behaviour may provide a partial explanation. On balance, however, 
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it seems more likely that the major obstacle is structural: an inherent orientation of 
the health services towards the needs of women rather than those of men. 
3.4.1 Healtlt seeking beltaviour 
Govender & Penn-Kekana (Govender and Penn-Kekana, 2007) recently 
undertook a comprehensive review of the evidence on gender and health access in 
developing countries. Focusing on experiences of care for TB and depression, the 
authors found that men and women understood and spoke about illnesses 
differently and had different health seeking behaviour. 
One such difference may arise from prevailing beliefs about masculinity and 
what it means to be a man (Braitstein et al. , 2008a, Govender and Penn-Kekana, 
2007, Nattrass, 2006, Muula et al., 2007). Shared notions that a man should be 
' strong, independent and self-reliant' (Govender and Penn-Kekana, 2007) may 
prevent men from accessing health care at early stages of illness, HIV-related or 
other. Indeed, a review of South African men's role in the response to HIV/ AIDS 
suggests that 'illness (be it of self or one's partner) seem[s) to interfere with the 
script of being a "real" man' (Kometsi, 2004). 
Another reason for disparities in accessing health services may be that 
women seek and receive treatment earlier than men due to their increased 
exposure to PHC services. In addition to their own clinic visits, women generally 
accompany sick family members to clinics (Muula et al., 2007). This increased 
exposure to clinics and health professionals may increase the likelihood that 
women are diagnosed and treated for health problems earlier than men. A study 
by Bertakis and colleagues (Bertakis et al., 2000) provides some evidence in 
support of this argument. Researchers explored why women were more likely than 
men to be diagnosed with depression by their primary health care giver. They 
found that women sought and received care at the primary care level, while men 
accessed more in-patient care. They reported a significant association between 
number of clinic visits and diagnosis of depression. 
Cultural norms may also limit men' s access to health care. Health care 
services in developing countries are run predominantly by women (Muula et al. , 
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2007). In patriarchal societies, men may be reluctant to consult with female 
providers, particuJarly on sensitive issues such as sexually transmitted infections 
(Govender and Penn-Kekana, 2007). 
While these arguments may provide some explanation of gender differences 
in access to HAART, the evidence is not entirely convincing. In a recent paper 
exploring gender differences in access to HAART, Nattrass (Nattrass, 2006) 
concluded that gendered norms prevented men from acknowledging weakness and 
seeking medical attention. A review of the literature suggests that, in fact, this 
may not be the prime obstacle. 
3.4.2 Gender orientation of health services in developing countries 
A more compelling explanation for the disparities in access to health care 
may be that primary health care services in most developed countries focus more 
on the health needs of women than those of men (Braitstein et al. , 2008a, Lawn 
and Wood, 2006). Women can access a range of reproductive and child health 
services targeting healthy young women of reproductive age. In contrast, men are 
offered few, if any, sexual and reproductive health services (Varga, 2001 ). Indeed, 
Mehta (Mehta et al., 2004), describing work with South African men in clinics 
and communities, suggest that ' men are generally the forgotten reproductive 
health care clients' . In a review of sexual and reproductive health and men in sub-
Saharan Africa, Varga (Varga, 2001) called males ' the forgotten fifty per cent' . 
Could it be true, as Hawkes (Hawkes and Hart, 2000) argues, that women are 
regarded as having rights regarding reproductive health while men have 
responsibilities? 
In South Africa, the limited primary health care services for men consist 
mainly of curative services for STis and TB (Lawn and Wood, 2006). As men are 
not being offered services at a primary health care level, they are less likely than 
women to seek and receive appropriate primary health care at earlier stages of 
ilJness (Govender and Penn-Kekana, 2007). Consequently, men may be less likely 
to be diagnosed at an early stage of HIV due to their limited interaction with 
primary health care services. 
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In addition, men have less access than women to voluntary counselling and 
testing (VCT) for HIV. HIV testing is not routinely offered in all health care 
facilities (National Department of Health, 2004a, SAN AC, 2007). Women are 
offered routine VCT through antenatal programmes and are also more likely to be 
offered VCT due to their increased exposure to clinics and health professionals. In 
contrast, men would be offered VCT in STI, TB or general curative services 
(Lawn and Wood, 2006). These men would tend to be sicker than the women 
being referred from reproductive health services. 
The South African government has attempted to address existing gaps in 
access to testing (National Department of Health, 2004a). The National Strategic 
Plan (NSP) aims to increase provider-initiated VCT in all health settings, 
primarily STI, TB, antenatal, family planning and general curative services. 
Unfortunately VCT in these settings will not identify men requiring HAART at 
earlier stages of disease, as has been illustrated. 
The NSP also fails to address other needs of men in the PHC services. The 
special needs of women and children are prioritised for treatment, care and 
support. There is, however, no mention of the special needs of men, other than 
those of men who have sex with men. In fact, there is almost no mention of men 
in the entire NSP. As Jordaan (Jordaan, 2006/7) argues, 'ignoring half of the 
population and in effect making the other half solely responsible for HIV 
prevention cannot be a durable strategy' . 
3.5 Summary 
IIlV / AIDS continues to spread unabated through the world. Southern 
Africa is the epicentre of the HIV/ AIDS epidemic, home to nearly one third of all 
people living IIlV. South Africa has the highest prevalence of IIlV in the world, 
with women comprising 55% of those infected. Data on the natural history of HIV 
suggest that there may be gender differences in progression to AIDS and death. 
This might be due to biological, social and/or structural factors. 
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Access to HAAR T has transformed the prospects of people living with 
IDV/AIDS, reducjng morhjruty and mortality and allowing HIV/AIDS to be 
treated as a chronic managed disease. For some years, there was only very limited 
access to HAART due to the prohibitive cost. However, international advocacy 
has reduced the costs substantially and many developing countries are now 
offering HAART. With increasing numbers of people - predominantly women -
on HAART through public health systems, it is essential to understand the impact 
of gender on access and responses to antiretroviral therapy. 
It is biologically plausible that women and men may respond rufferently to 
HAART. It is also likely that disparities in access to HAART could impact on 
outcomes. Numerous studies have explored these issues, with conflicting results. 
However, most analyses that adjust for baseline factors find no significant 
rufference in outcomes. It is possible that apparent gender differences in survival 
are mediated by the degree of disease at start of treatment. Certainly, it seems that 
people who start HAART with more advanced disease are likely to have worse 
outcomes than those who are diagnosed and treated at earlier stages. 
The reasons why women may be diagnosed earlier than men in developing 
countries are complex and difficult to quantify. They include differences in health 
seeking behaviour and the existing gender orientation of primary health services. 
Further research is needed to understand gender-based differences in access to 
health services in order to ensure that women and men are ruagnosed and initiated 




4.1 Study design 
This cohort study explored gender differences in the survival of HIV-
infected people enrolling on a treatment programme at the Hannan Crusaid 
Treatment Centre (HCTC), an antiretroviral therapy (ART) clinic based in 
Gugulethu, Cape Town. The study was a retrospective review and secondary 
analysis of the patient records contained in the HCTC database. During routine 
assessment, demographic, clinical and other data on 2843 treatment-nai:ve adults 
were collected between September 2002 and April 2007. All patients who had 
started treatment in another facility were excluded as being non-nai:ve. 
Numerous HAART service evaluations (Bekker et al., 2006, Etard et al., 
2006, Stringer et al., 2006) have reported high rates of early mortality, which tend 
to decline after the first few months. It was anticipated that in this cohort, the 
major burden of mortality would fall within the first year. Most HAART cohort 
studies only report data from the date of initiation of HAART. However, Lawn 
(Lawn et al., 2006a) found that after three years of a HAART programme, deaths 
in the period between entry and initiation ofHAART accounted for nearly half of 
the total mortality. Thus, this analysis followed patients from the first visit at the 
clinic to one year after the initiation ofHAART. 
4.2 Study site and population 
Based in the Gugulethu Community Health Centre, the HCTC provides 
HAART to residents ofNyanga. Nyanga is a predominantly African township on 
the outskirts of Cape Town with a population estimated at 300 000. Most 
inhabitants are of low socio-economic status, as are the majority of black South 
Africans. Antenatal HIV seroprevalence in 2003 was 28%. The patient profile is 
representative of patients accessing HAART in South Africa. Originally 
established for research, the HCTC was one of the first sites in the Western Cape 
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to roll-out antiretrovirals in September 2002 (Bekker et al. , 2003 , Bekker et al., 
2006, Lawn et al. , 2006a). 
The referral system comprises nine primary health care (PHC) clinics, two 
community health care centres (CHCs) and a Midwife Obstetric Unit (MOU) that 
provides antenatal care. The PHC clinics are run by the city health services and 
offer primary care for HIV, TB and sexually transmitted infections (STis). The 
CHCs offer general medical services for adults, often with HIV clinics. ARV 
therapy is provided to patients on the basis of the 2002 guidelines of the World 
Health Organisation (WHO), i.e. WHO stage 4 disease or CD4 cell count below 
200 cells/µL. All individuals referred to HCTC have already been identified as 
requiring ARV therapy. In line with provincial guidelines, the clinic offers first-
line HAART and a second-line regimen for those who fail treatment. Most 
patients have not previously received HAART and receive standard first-line 
therapy (Lawn et al. , 2006a). First-line treatment in South Africa for men, women 
of child-bearing potential and pregnant women consists of stavudine, lamivudine 
and nevirapine (NVP). For any conditions where NVP is contra-indicated, 
efavirenz is substituted (National Department of Health, 2004b ). 
The average time from first visit to initiation ofHAART is approximately 
one month, during which time patients undergo clinical and psycho-social 
assessment. Typically, this includes clinical staging, blood tests in order to 
establish baseline levels of CD4 cell count and HIV viral load, and collection of 
demographic data. 
In addition, patients undergo three group treatment-readiness sessions to 
ensure that they are ready to initiate and remain on long-term therapy. Patients are 
then assigned to a community-based therapeutic counsellor from the Sizophila 
programme. The counsellors provide support on site and follow up with home 
visits. This therapeutic support contributes to high rates of adherence and viral 
suppression and low rates ofloss-to-follow-up (L TFU) (Lawn et al. , 2006a, Orrell 
et al. , 2003). Patients are encouraged to disclose their HIV status to a friend or 
family member, as additional treatment support. After enrolment, adults on first-
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line HAART see a medical doctor at four, eight and 16 weeks and every four 
months thereafter, for cJinjcaJ, immunological and virological assessment. All 
treatment is free of charge, and drugs are dispensed every two months. At each 
visit, patients see the therapeutic counsellor for psychosocial support, and to 
return unused pills. 
This cohort has been well-studied but there has been no systematic 
evaluation of the impact of gender on survival and LTFU after entry into the 
programme. Previous studies have established that there is high early mortality in 
this programme (Lawn et al. , 2006a). However, previous analyses have not 
examined whether there was a gender difference in mortality in the pre-treatment 
period. Over three years, only 21 individuals (2.3%) were lost-to-follow-up, but 
there was no analysis of gender differences within this group. 
4.3 Definitions 
'Deaths pre~HAART' were those patients who died after entry into the 
programme but before initiating HAART. 'Permanent deferrals ' were those 
individuals who did not ever initiate HAART but did not die pre-HAART. 
'A waiting treatment' were those who had not initiated treatment at the date of 
censoring. ' Started treatment' were those who started HAART. ' Deaths on 
HAART' were patients who died while on treatment. 'Transfers out' were those 
individuals who were transferred to another facility, having initiated therapy. 
'LTFU on HAART' were patients who started HAART and have been absent 
from the clinic for longer than 3 months. ' Still on treatment' were patients who 
were still on HAAR T at the date of censoring. 
4.4 Measurements 
Demographic and clinical data were collected via standard HCTC data 
collection forms (Appendix 8.4) and entered onto an MS Excel database. 
Variables treated as continuous in this analysis were: age (years), viral load at 
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baseline (log copies of HIV RNA/ml), CD4 cell count at baseline (cells per 
microlitre), haemoglobin (g/d.L) and income (R/month). Categorical variables 
were: gender ( 1 =female, 2=male ), WHO stage at baseline (I & II, III or IV), CD4 
cell count ( <50, 51-100, 101-150 and > 150 cells/µL), and income (RO/month, Rl-
R699/month or >=R700/month). There were data on education level 
(primary/secondary) for 2544 subjects. As 2303 (91 % ) of these had at least 
secondary level education, education level was excluded from the analysis. In 
order to assess associations with clinical outcomes at 48 weeks, two responses 
variables were generated: CD4 cell count at 48 weeks (continuous) and viral 
suppression at 48 weeks (binary). 
Generally, there was a period of about four weeks between patients' first 
visit and the start of treatment. During this time, patients underwent screening and 
treatment-readiness. The first visit was known as week minus 4, or 'week-4 ' . The 
visit at which patients were started on treatment was regarded as the baseline visit 
or 'week O' . However, for a few patients who were very ill, or who had previously 
undergone treatment-readiness sessions elsewhere, their first visit was also 
regarded as their baseline (visit 0), at which they started HAART. In order to 
include these in the analysis, the date of starting treatment was recorded as one 
day later than their first visit. One patient died on the day s/he started treatment. In 
order to include this death in the analysis, date of death was recorded as one day 
later than the start of treatment. The clinic defines patients as LTFU if there has 
been an absence of three months since their last clinic visit. As patients receive 1-
2 months HAART at a visit, this means that they will have missed 1 or more 
months ofHAART. Overall, five patients were recorded as lost-to-follow-up 
(LTFU) on their start dates. To include their data, the date ofLTFU was estimated 
at three months after the start date. 
The data set contained CD4 cell counts and viral load measures taken on 
specific visits. In instances when these were not taken at a particular visit, the data 
sometimes included an interim measure taken between visits. This analysis 
assumed that any such measure would be used to represent the CD4 or viral load 
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of the previous missed visit. Where, for example, the CD4 cell count from a week 
4 visit was missing but there was a value for a measure taken before the week 8 
visit, the measure taken between the two visits was used as the value for the week 
4 visit. 
WHO staging was done by medical doctors at screening visits, according to 
the 2002 WHO clinical guidelines. CD4 cell count and HIV RNA viral load 
testing were done in an on-site laboratory. CD4 cell count was done using flow 
cytometry (FACSCount™, Becton Dickinson, Franklin Lakes, NJ, USA). HIV 
RNA viral load was tested with branch DNA hybridisation technique (VersantTM 
HIV-1 RNA 3.0 branched chain DNA assay (Bayer Healthcare, Leverkusen, 
Germany). 
4.5 Analysis 
Cleaning, coding and analysis of data were done in Intercooled ST AT A 10. 0 
for Windows (STATA Corporation, College Station, TX). In the exploratory data 
analysis, the distribution of continuous variables was tested in histograms. As the 
variables were non-parametrically distributed, the study reported medians and 
inter-quartile ranges. Differences between groups were tested using the Wilcoxon 
sum rank test for medians and the chi-square test for proportions. 
Observation time was calculated in three different ways. The first time 
period was the observation time from the patient's first visit to one of four 
outcomes: (1) death before initiating HAART; (2) permanent deferral of 
treatment; (3) awaiting treatment at date of censoring; or ( 4) initiation of 
treatment. The second time period was the observation time from the start of 
treatment to one of four possible outcomes: (1) death on HAART; (2) transfer to 
another facility; (3) LTFU on HAART; or ( 4) still on treatment at date of 
censoring. The third time period was the total observation time from the first visit 
to the closure of the database, 24 April 2007, with six possible outcomes: (1) 
death before or on HAART; (2) alive on treatment at censoring date; (3) awaiting 
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HAART at censoring date; (4) permanent deferral before initiation ofHAART; 
(5) transferral to another facility while on HAART; (6) LTFU on HAART. 
Age, viral load and CD4 cell count were modelled as continuous and 
categorical variables, and different cut-off points were tested. Age was retained as 
a continuous variable as its association with death was continuous. Although the 
effects of CD4 cell count and viral load were continuous, they were modelled as 
categorical variables in line with current practice. In testing categorical variables 
for significance, this analysis reported the global p-value instead of separate p-
values for each level of the variable. Haemoglobin was measured at the baseline 
visit (week 0) and not at the first visit (week -4). However this measure was 
included here as a baseline characteristic in analysis, since there is likely to be 
minimal variability in haemoglobin over this short (2-4 week) period. 
Haemoglobin measurements were only available for 1853 patients, and it is 
included here only as a descriptive measure. As the inclusion of haemoglobin in 
multivariate models would have required dropping an additional 600 observations, 
it was not included in a final model. 
The comparative survival by gender in the three observation periods was 
estimated and compared with Kaplan-Meier survival curves and use of the log 
rank test. Survivor functions were generated for each of the three observation 
periods, with a comparison at the same time points by gender. Cox's proportional 
hazards regression was used to estimate the crude impact of the variables on the 
hazard of death in the three groups. Cox's proportional hazards regression was 
also used to investigate the effect of gender on the hazard of death after adjusting 
for participant demographic and HIV disease-related characteristics. The best-fit 
model was selected on the basis of changes to the crude association between 
gender and mortality, as well as the number of observations being lost with the 
addition of each new variable. 
Cox's proportional hazard regression models rely on the assumption that 
the effect of variables on survival time remains constant over time, i.e. the hazards 
are proportional. Thus, a test for proportional hazards is equivalent to testing for a 
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non-zero slope in a regression of Schoenfeld residuals on a function of time 
(Cleves et al ., 2002). This analysis tested the proportional hazards assumption 
using Schoenfeld and scaled Schoenfeld residuals on the rank of time (Appendix 
8.3.1). In addition, Cox-Snell residuals were generated to assess overall model fit 
(Cleves et al. , 2002). If the line did not deviate much from the reference line, the 
models appeared to provide a good fit for the data. 
Logistic regression was used to estimate the crude impact of the variables 
on the binary response variable (viral suppression at 48 weeks). It was also 
utilised to investigate the effect of gender on viral suppression at 48 weeks, 
adjusted for participant demographic and HIV disease-related characteristics. The 
model was checked by testing the general fit and the adequacy of the linear 
component (Appendix 8.3.2). The goodness-of-fit statistic was generated, with a 
p-value >0.05 showing that the model was a fairly good fit for the data (Juul, 
2006). 
Multiple linear regression was used to estimate the crude impact of the 
variables on the continuous response variable (CD4 cell count at 48 weeks). It was 
also used to explore the effect of gender on CD4 cell count at 48 weeks after 
adjustment for baseline characteristics. The model was checked by testing the 
normality of residuals and by assessing whether collinearity was present 
(Appendix 8.3.3). Residuals were plotted in a histogram and a two-way scatter 
and assessed for normality. Individual and global variance inflation factors (VIFs) 
were calculated. An individual VIF > 10 would suggest that this variable may be 
redundant in the model (Juul, 2006). Logistic regression was also used to estimate 
the crude impact of sex on the binary response variables (CD4 cell count at 48 
weeks >200 vs <200; and >350 vs <350). 
The study tested if degree of disease was acting as a mediator that might 
explain the apparent association between gender and death. As shown in Figure I 
below, for a disease parameter to act as a mediator, it must be part of the causal 
pathway connecting exposure (gender) to disease (AIDS death) (Susser et al. , 
2006). If this is the case, it is not desirable to remove its effect, as with 
confounding, but rather to understand how this factor acts together with gender to 
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cause death. It is not possible to distinguish between confounders and mediators 
on the basis of data alone (Susser et al ., 2006), although tests can provide 
evidence to corroborate a biologically plausible hypothesis. It is biologica11y 
plausible that instead of gender causing AIDS mortality directly, gender may 
cause differences in CD4 cell counts which in tum cause AIDS deaths. Regression 
co-efficients from adjusted models were used to examine the potential mediating 
role of individual disease parameters in the association between gender and 
mortality using the Sobel test (Shrout and Bolger, 2002). The Sobel test tells 
whether the indirect effect of the independent variable on the dependent variable 
through the mediator variable is significant. It does this by testing the hypothesis 
that there is no difference between the direct effect and the total effect. The Sobel 
test is believed to be superior, for example, to the Baron & Kenny method, in 
terms of power, Type I error, suppression effects, addressing the significance of 
the indirect effect. It is limited by the underlying assumption that the sampling 
distribution is normal(Tein and MacKinnon, 2003). Throughout the analysis, 2-
sided statistical tests at alpha=0.05 and 95% confidence intervals were used unless 
otherwise indicated. 





The key ethical issues that arose in undertaking this analysis involved 
aspects of beneficence, justice and, to some extent, autonomy. 
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Beneficence implies that patients are not intentionally harmed and that 
possible benefits to patients are maximised while possible harms are minimised 
(Joubert and Ehrlich, 2007). This analysis posed no risk or discomfort to the 
patients since it did not involve additional human subjects research and only 
utilised data that had already been collected as part of clinic routine. This data 
collection was formally approved by the UCT Research Ethics Committee 
(Appendix 8.1). 
The concept of justice in medical research ethics is closely tied to that of 
beneficence. However, it raises additional questions for researchers: who should 
benefit from the research, and who should bear the burden of such research 
(Joubert and Ehrlich, 2007)? In this study, participants represent South Africans 
accessing HAART through the public health system. Although the analysis will 
not directly benefit the participants bearing the burden of the research, it could 
potentially offer some benefit to this broader community. It could increase 
existing knowledge about the impact of gender on survival of people in HAART 
programmes in developing countries. By analysing the comparative survival of 
men and women pre- and on-treatment, and by exploring whether this is mediated 
by degree of disease, the study could increase knowledge about gender differences 
in HAART programmes. It could support policy aimed at improving access to 
public health services and national HAART programmes. If no mediation is 
found, this information could guide future research into other factors impacting on 
survival. The requirement of justice appears to be satisfied. 
With respect to autonomy, alJ subjects have already been provided with 
information about ongoing research at the HCTC. At their first visit, subjects sign 
an informed consent fonn confinning that they understand the nature of the 
research and agree to the collection of relevant data to this end. As the study 
utilises a data base which does not contain patient identifiers, patient 
confidentiality is ensured. A confidentiality agreement at the HCTC further 
protects patients' rights. Patients who choose not to sign the informed consent 
form still receive treatment. 
-38-
5 RESULTS 
5.1 Baseline characteristics 
A total of 3162 adults were referred for HAAR T at HCTC between 2 
September 2002 and 23 April 2007. Patients who had started HAART at another 
facility and then transferred into the programme were excluded (n=319). This 
analysis includes the remaining 2843 HAART-na1ve individuals, 1889 (66%) of 
whom were female. An estimated 8% of these women were pregnant at 
programme entry, and may thus have initiated HAART at a higher CD4 count 
and/or lower WHO stage than others entering the programme. A total of 329 
(12%) started with CD4 counts above 200 cells/µL, of whom 246 were female and 
83 male (p<0.001). 
As shown in Table l, there were significant gender differences in key 
baseline characteristics on entry into the HAAR T programme. On average, 
women were younger than men (31 years vs 36 years, p<O.001) and had higher 
median CD4 cell counts at baseline (112 vs 89 cells/µL; p<0.001). Women had 
significantly lower haemoglobin counts than men (10.7g/dL vs 12.2 g/dL; 
p<0.001). Haemoglobin counts for women and men were lower than the bottom 
limit of the normal ranges 1. 
More women than men (28% vs 16%) presented with early stage disease, 
classified as WHO stage T & TT, while more men than women (29% compared 
with 20%) were classified as WHO stage IV at entry (p<0.001). The median log 
viral load was higher among men (4.97, IQR, 4.55-5.40) than among women 
(4.78, IQR, 4.30-5.20; p<0.001). Approximately half of all females and males 
earned no monthly income, and 240 ( 16%) of females and 49 (7%) of males 
earned Rl-R700/month (p<0.001). 
1 
According to the Oxford Handbook of Clinical Medicine, normal haemoglobin ranges are l l.5-16g/dL for 
women and 13-18g/dL for men. 
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Table 1: Baseline characteristics of cohort at entry to HAART programme 
Total 
rnhort \\ Olllt'll \ lt'n 
( 'ha rncteris tir (n=28-B) (n=I889) (n=9S-I l p-, alue 
Age, median (y) (IQR) 33 31 36 p<0.001 
(28-39) (27-37) (31-42) 
Haemoglobin (g/dL), median (IQR) 11 10.7 12.2 p<0.001 
(9.8-12.4) (9.6-11.8) (10.5-13.6) 
CD4 cell count (cells/µL), median (IQR) 105 .5 112 89 p<0.001 
(48-164) (57-169) (38-154) 
CD4 cell count (cells/µL) , n (%) p<0.001 
<50 627 367 260 
(26%) (23%) (33%) 
51-100 521 338 183 
(22%) (21%) (23%) 
101-150 515 368 147 
(21%) (23%) (18%) 
> 150 745 541 204 
(31%) (33%) (26%) 
WHO stage at entry, n (%) p<0.001 
I& II 679 528 151 
(24%) (28%) (16%) 
III 1508 979 529 
(53%) (52%) (56%) 
IV 650 378 272 
(23%) (20%) (29%) 
mv RNA level (log10 copies/ml), median 4.83 4.78 4.97 p<0.001 
(IQR) ( 4.38-5.28) (4.3-5.2) (4.55-5.4) 
mv RNA level (log10 copies/ml ), n (%) p<0.001 
<= 5 log 1349 966 383 
(59%) (63%) (52%) 
> 5 log 920 571 349 
(41%) (37%) (48%) 
Monthly income, n (%) p<0.001 
No income 1196 821 375 
(54%) (54%) (53%) 
Rl-R700 289 240 49 
(14%) (16%) (7%) 
>R700 730 448 282 
(33%) (39%) (40%) 
5.2 Enrolment and follow-up 
The data were ctivided into three analyses based on time spent in the 
programme (Figure 2). These were: pre-HAART time (from entering the 
programme to initiation ofHAART), time on HAART (from start of therapy to 
the end of the period of observation) and total cohort time (pre- and on-HAART). 
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Figure 2: Description of an adult .HAART-naive antiretroviral therapy 
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The total follow-up time was 2102 person-years, 1437 person-years of which were 
for female patients (Table 2). 
Table 2: Follow-up time 
Total Females \lales 
Total person-years 2102 1437 665 
Pre-HAAR T person-years 451 291 160 
On-HAART person-years 1651 1146 505 
Deaths 285 166 119 
(58%) (42%) 
During the pre-HAART period, 647 (23%) adults were censored. Of these, 
129 were censored due to death. Treatment was permanently deferred for 349 
individuals. The remaining 169 were still awaiting treatment at the end of the 
period. During the on-HAAR T period, 363 ( 17%) were censored. A total of 156 
patients died, 70 were transferred to another facility and 137 were LTFU. In the 
total cohort, 1010 (36%) were censored. Overall, 285 patients died, 169 were 
awaiting treatment and 349 had HA ART permanently deferred. A further 70 
individuals were transferred to another facility and 137 were LTFU. 
5.3 Results for pre-HAART period 
5.3.1 Enrolment and follow-up: pre-HAART 
The pre-HAART period included a total of2843 HAART-na'ive adults who 
entered the programme but had not yet initiated HAART. During the pre-HAART 
period, a total of 647 (23%) subjects were censored. A total of 129 (5%) adults 
died and 349 (12%) had HAART permanently deferred. A total of 169 (6%) were 
still awaiting treatment at the date of censoring. The total duration of follow-up 
was 451 person-years. Females were followed for a total of291 person-years, and 
males for 160 person-years. The median duration of follow-up in the pre-HAART 
period was 35 person-days (IQR, 26-63). Among females, the median follow-up 
was 35 person-days (IQR, 28-62). The median follow-up among males was 35.5 
person-days (TQR, 28-69). 
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5.3.2 Mortality pre-HAART 
Table 3 compares baseline characteristics between those who did not start 
HAART and are still alive with those who started HAART. 
Table 3: Baseline characteristics by mortality: pre-HAART 
Female, n (%) 1479 335 75 
67%) {65%) 0.244 (58%) 
Age, (y), median (IQR) 33 32 34 
28-39 27-39 0.287 29-40 
CD4 cell count (cells/µL), median 102 164 49 
IQR 48-158) 86-271 <0.001 22-110 
CD4 cell count (cells/µL), n (°lo) <0.001 
<50 524 48 55 
26% 17% 53% 
51-100 468 34 19 
23% 12% 18% 
101-150 452 47 16 
22% 17% (15% 
>150 576 155 14 
(29%) (55%) {14%) 
WHO stage at entry, 11 (%) <0.001 
I&II 495 179 5 
23% 35% (4% 
III 1197 248 63 
(56%) (48%) 49%) 
IV 502 87 61 
(23% (17% 
HIV RNA level, log10 copies/ml, median 4.84 4.64 
IQR) 4.4-5 .3 3.94-5.17 <0.001 
HIV RNA level, log10 copies/ml, n (%) 
<= 5 log 1181 145 23 
60% 68% 0.015 32% 
> 5 Log 803 68 49 
40% 32% 68% 
Monthly income, 11 (%) 0.657 
No income 1007 124 65 
54% 52% 62% 
Rl- R700 243 36 10 
13% 15% 9% 
>R700 621 79 30 
(33%) (33%) (29% 
2 p-value for comparisons between those who did not start HAART and are not dead vs those who started 
HAART 










Table 3 also compares characteristics of those who died before starting HAART 
with those who started HAART. 
There was high early mortality, with 129 (45%) of the total cohort deaths 
occurring in this period. The incidence rate was 28.6/100 person-years of 
observation. The incidence rate among women was lower than among men 
(25.8/100 vs 33.8/100 person-years; p=0.133). 
On average, those who died during the pre-HAART period had lower 
median CD4 cell counts than those who started treatment (49 vs 102 cells/µL; 
p<0.001). They also had higher log viral loads than those who started HAART 
(5.38 vs 4.84; p<0.001 ). There were differences in WHO stage at entry. Those 
classified as stage I & II, III or IV among the deaths and those initiating HAART 
were respectively 4% vs 23%, 49% vs 56%, and 47% vs 23% (p<0.001). There 
were no significant differences in median age and monthly income between those 
who died and those who started HAART. 
Table 3 also compares baseline characteristics of those who started HAART 
with those who did not start HA ART and did not die in this period. There was no 
significant gender difference between the proportions of men and women who did 
and did not start HAART (p=0.244). Those who had not started HAART and were 
not dead tended to have higher CD4 cell count than those who started HAART 
(164 vs 102 cells/µL ; p<0.001). Those who started HAART had higher median 
log viral loads than those alive and not starting therapy ( 4. 84 vs 4.64; p<0.001 ). 
Those classified as stage T & TT, TTT or TV among those alive and not on HAART 
vs those who started HAART were respectively 35% vs 23%, 48% vs 56%, and 
17% vs 23% (p<0.001). The median age was not different between these groups 
(p=0.287), nor was monthly income (p=0.657). 
5.3.3 Crude association between baseline cl,aracteristics and mortality: pre-
HAART 
Table 4 shows the crude associations between baseline characteristics and 
the hazard of mortality. 
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Table 4: Crude association between baseline characteristics and mortality: 
pre-HAART 
p-
( haractrristic J-11{ IJS 'X, ( I , alur 
Gender 
Female 1.0 
Male l.3] (0.93-1.86) 0.131 
Age 1.02 (l.00-1.04) 0.086 
CD4 cell count (cells/µ!) 0.99 (0.99-0. 99) <0.001 
CD4 cell count (cells/µL) <0.001 
<50 1.0 
51-100 0.38 (0.23-0.64) 
101-150 0.30 (0.17-0.52) 
>150 0.15 (0.08-0.27) 
WHO stage at entry <0.001 
I & II 1.0 
III 5.91 (2.38-14.71) 
IV 13.64 (5.48-33.96) 
HIV RNA level, log10 2.92 (1 .87-4.55) <0.001 
copies/ml I! 
<= 5 Log 1.0 
> 5Log 3.0 (1 .83-4. 94) 
Monthly income 0.089 
No income 1.0 
Rl-R700 0.60 (0.31-l.18) 
>R700 0.66 (0.43-1.01) 
Male gender increased the risk of mortality (HR 1.31, 95% CI, 0.93-1.86; 
p=0.131) as did age (HR for a one-year increase in age, 1.02, 95% CI, 1.00-1.03; 
p=0.086). Those presenting with higher CD4 cell counts at baseline were less 
likely to die in the pre-HAART period than those with lower CD4 cell counts (HR 
0.99, 95% CI, 0.99-0.99; p<0.001). This benefit was most marked among those 
who had > 150 cells/µL at baseline compared with <50 cells/µL (HR 0.15, 95% 
CT, 0.08-0.27; p<0.001 ). There was a six-fold increase in the relative hazard of 
mortality among those classified as WHO stage III compared with WHO stage I & 
II at entry (HR 5.91 , 95% CI, 2.38-14.70) and a fourteen-fold increase among 
those classified stage IV compared with stage I & II (HR 13.64, 95% CI, 5.48-
33.96; p<0.001). For every one log increase in the baseline HIV RNA level, there 
was a three-fold increase in hazard (HR 2.92, 95% CI, 1.87-4.55; p<0.001). Those 
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earning any income had a 40% reduction in risk compared with those earning 
nothing (HR 0.60, 95% CT, 0.31-1 .18; p=0.089). The corresponding Kaplan-Meier 
curves (Figure 3) and survival estimates (Table 5) suggest that there was no 
difference in survival between women and men before starting HAART, 
unadjusted for baseline characteristics. 
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Table 5: Kaplan-Meier survival estimates: pre-HAART 
Tim<' 
(da~s) F<'maks \)ales 
0 1.000 1.000 
30 0.982 0.971 
60 0.962 0.935 
90 0.916 0.917 
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5.3.4 Adjusted effect of male gender on mortality in the pre-HAART period 
Proportional hazards models were used to assess the adjusted effect of male 
gender on the risk of mortality (Table 6). After adjustment for WHO stage at 
entry, the hazard ratio for male gender was reduced from 1.31 (95% CI, 0.92-
1.86) to 1.10 (95% CI, 0.77-1.56). It was further reduced to 1.07 (95% CI, 0.74-
1.53) after adjusting for both WHO stage and age. Adjusted for WHO stage, age 
and CD4 cell count at entry, male gender did not appear to be a risk factor for 
death (HR 1.01, 95% CI, 0.67-1.51). 



















1.01 o.67-1.5 r 
1.0 
0.46 (0.27-0. 78) 
0.42 (0.24-0. 75 
0.22 0.12-0.40) 
In a separate analysis (not shown), there was evidence to suggest that 
disease parameters mediate the apparent association between gender and death 
pre-HAART. The Sobel test found significant associations with CD4 cell count 
(p=0.044) and WHO stage at entry (p=0.003 ). Supporting this, the mediating role 
can be seen plainly in Table 6 above. Comparing the crude and adjusted hazard 
ratios, there was a marked attenuation, amounting to a 30% reduction in the log 
hazard for death ( comparing gender coefficients from models 1 and 4 ). 
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5.4 Results for on HAART analyses 
5.4.1 Enrolment &follow-up: on HAART 
The on-HAART period includes a total of2196 HAART-narve adults who 
initiated HAART after entering the programme. During this period, 363 (16%) 
were censored. This comprised 156 (7%) deaths, 70 (3%) transferrals to another 
facility and 137 (6%) who were LTFU. The total duration of follow-up was 1651 
person-years, of which 1146 person-years were among female patients and 505 
person-years among males (Table 2). The median duration of follow-up in the on-
HAART period was 365 person-days (IQR, 183-365). Among females, the 
median follow-up time was 365 person-days (IQR, 202-365). The median follow-
up time among males was 343 person-days (IQR, 145-365). 
5.4.2 Mortality: on HAART 
Table 7 compares baseline characteristics of those who died with those who 
did not die and were not transferred to another facility or LTFU in the on-HAART 
period. It also compares characteristics of those who were L TFU with those who 
did not die, were not L TFU and were not transferred. In this period, 55% (n= l 56) 
of the total cohort deaths occurred. The incidence rate was 9.45/100 person years 
of observation. More than half of those who died ( 5 8%) were female (p=O.010 ). 
The incidence rate was lower among women than men (7.9/100 person-years vs 
12.9/100 person-years; p=0.003). 
On average, those who died had lower haemoglobin counts at baseline than 
those who did not die (p<0.001 ). Overall , the patients who died were older 
(p=0.007) and had far lower median CD4 cell counts at baseline than those who 
survived (p<0.001). The proportions of those who died vs those who survived 
with CD4 cell counts <50, 51-100, 101-150 and > 150 cells/µL respectively were 
48% vs 25%, 22% vs 21%, 14% vs 22%, and 16% vs 32% (p<0.001). There were 
significant differences in WHO stage at entry. Those classified as Stage I & II, III 
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Table 7: Baseline characteristics by mortality and loss-to-follow-up: on 
HAART 
'\ot died. not 
1.rn or 
( ·11aracteristic transferred Died p-, alue ~ I.TH 
Female, n (%) 1798 91 87 
(67%) (58%) 0.010 (64%) 
Haemoglobin, (g/dL), 11.l 10.l 11 
median (IQR) (9.8-12.4) (8.9-11.3) <0.001 (9.7-12.3) 
Age, median (y) (IQR) 32 35 31 
(28-39) (29-43) 0.007 (26-37) 
CD4 cell count (cells/µL), 108 53 114 
median (IQR) (52-166) (14-112) <0.001 (40-170) 
CD4 cell count (cells/µL) , n (°lo) <0.001 
<50 555 72 41 
(25%) (48%) (30%) 
51-100 488 33 24 
(21%) (22%) (18%) 
101-150 494 21 24 
(22%) (14%) (18%) 
>150 721 24 47 
(32%) (16%) (34%) 
WHO stage at entry, n (%) <0.001 
I& II 667 12 35 
(25%) (8%) (26%) 
m 1427 81 72 
(53%) (52%) (53%) 
IV 587 63 30 
(22%) (40%) (22%) 
HIV RNA level, log1o copies/ml, 4.82 5.04 4.84 
median (IQR) ( 4.35-5.27) (4.59-5.44) 0.001 (4.35-5.4) 
mv RNA level, log10 copies/ml 
<=5 Log 1279 70 81 
(60%) (49%) (60%) 
> 5 Log 846 74 54 
(40%) (51%) (40%) 
Monthly income, n (%) 0.015 
No income 1104 92 86 
(53%) (63%) (66%) 
Rl-R700 270 19 11 
(13%) (13%) (9%) 
>R700 695 35 32 
(34%) (24%) (25%) 
4 p-value for comparison between those who died and those who did not die, were not L TFU or transferred to 
another facility 
5 p-value for comparison between those who were L TFU and those who did not die, were not L TFU or 
transferred to another facility 
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p-









or IV among the deaths and survivors in the programme were respectively 8% vs 
25%, 52% vs 53%, and 40% vs 22% (p<0.001 ). On average, the median log viral 
load at baseline was significantly higher among those who died than among those 
still alive (5 .04 vs 4.82; p=0.001). More than half of those who died (63%) and 
those who did not die (53%) received no monthly income (p=0.015). 
5.4.3 Crude association between baseline cliaracteristics and mortality: on 
HAART 
Table 8 shows the crude association between baseline characteristics and the 
risk of death on treatment. In this time period, male gender increased the risk by 
57% (HR 1.57, 95% CI, 1.14-2.16; p=0.005). This is confirmed in the 
corresponding Kaplan-Meier curve (Figure 4) and survival estimates (Table 9). 
Table 8: Crude association between baseline characteristics and mortality: 
onHAART 
p-,aht<.' 
( hantl'tl'ristic UR 9S'X, ( I 
Gender 
Female 1.0 
Male 1.57 (1 .14-2.16) 0005 
Haemoglobin (g/dL) 0.83 (0.76-0.91) <0.001 
Age 1.03 (1.01 -1.05) <0.001 
CD4 cell count (cells/µ!) 0.99 (0.99-0. 99) <0.001 
CD4 cell count (cellshtl) <0.001 
<50 1.0 
51-100 0.47 (0.31-0.71) 
101-150 0.31 (0.19-0.51) 
>150 0.28 (0.18-0.45) 
WHO stage at entry <0.001 
I& II 1 .0 
Ill 2.73 (1.49-5 .00) 
IV 5.24 (2.83-9.71) 
IIlV RNA level, log10 copies/ml 1.45 (1.13-1.88) 0.004 
mv RNA level, log10 copies/ml 
<= 5 Log 1.0 
> 5Log 1.61 (l.16-2.24) 
Monthly income 0.022 
No income 1.0 
Rl-R700 0.80 (0.49-1.32) 
>R700 0.58 (0.39-0.86) 
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A one-unit increase in haemoglobin at baseline was associated with a 17% 
reduction in the risk of mortality (HR 0.83 , 95% CT, 0.76-0.91 ; p<0.001). The risk 
of death increased with age (HR for a one-year increase in age, 1.03, 95% CI, 
1.01-1.05; p<0.001). The risk was lower for those with higher CD4 cell counts at 
entry than those with lower CD4 cell counts (HR 0.99, 95% Cl, 0.99-0.99; 
p<0.001). This benefit was most marked among those with CD4 cell counts above 
150 cells/µL (HR 0.28, 95% CI, 0.18-0.45 ; p<0.001). Compared with those 
classified WHO stage T & TT at entry, there was a nearly three-fold increase in 
hazard among those classified stage III (HR 2.73, 95% CI, 1.49-5.00) and a five-
fold increase among those classified stage IV (HR 5.24, 95% CI, 2.83-9.71 ; 
p<0.001). For every one-log increase in IDV RNA level, there was a 45% increase 
in the risk of death (HR 1.45, 95% CI, 1.13-1.88; p=0.004). Increased income was 
associated with a reduction in risk. Those earning above R700/month had a 42% 
reduction in risk compared with those earning nothing (HR 0.58, 95% CT, 0.39-
0.86; p=0.022). 
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Ta bJe 9: KapJan-Meier survival estimates: men and women: on HAART 
Time 
(da~s) Females \I ales 
30 0.987 0.973 
60 0.978 0.946 
90 0.963 0.933 
120 0.958 0.925 
150 0.952 0.918 
180 0.948 0.914 
210 0.948 0.911 
240 0.946 0.909 
270 0.940 0.907 
300 0.934 0.902 
330 0.932 0.898 
360 0.930 0.895 
5.4.4 Adjusted effect of male gender on mortality in the period on HAART 
Proportional hazards models were used to assess the adjusted effect of male 
gender on the risk of death on HAART (Table 10). After adjusting for WHO stage 
at entry, the hazard ratio for male gender was reduced from 1.57 (95% CI, 1.14-
2.16) to 1.38 (95% CI, 1.00-1.91). It was further reduced to 1.25 (95% CI, 0.90-
1. 74) after adjusting for both WHO stage and age. Adjusted for WHO stage, age 
and CD4 cell count on entry, male gender increased the risk of death by 19% (HR 
1. 19, 95% CI, 0.88-1.97). 
TabJe 10: Adj usted effect of male gender on mortality: on HAART 
Female 
Male 



















1.25 1.19 ·o.88- l.9T 
1.00 1.00 
2.54 (1.39-4.67 2.35 (1.21-4.58) 
4. 76 2.56-8.86 3.93 1.98-7.80 





5.4.5 Mediation by degree of disease 
Utilising the Sobel test, there was evidence to suggest that both CD4 
(p=0.045) and WHO stage at entry (p<0.001) mediated the apparent association 
between gender and death on HA.ART. Supporting this, the mediating role can be 
seen plainly in Table 10 above. 
There was a marked attenuation between the crude and adjusted hazard 
ratios, amounting to a 38% reduction in the log hazard for death (comparing 
gender coefficients from models 1 and 4). 
5.4.6 Loss-to-follow-up on HAART 
Table 7 (pg 49) also compares baseline characteristics of those LTFU with 
those who did not die and were not transferred or LTFU while on HAART. Of the 
2196 patients who initiated HA.ART, 137 (6%) were LTFU within a year. Of 
these, 87 (64%) were female . There was no significant difference in gender 
distribution between those LTFU and those who were alive at one year (p=0.240). 
The median age was slightly lower among those L TFU than those who were 
retained on HA.ART (31 vs 32, p=0.037). Neither median CD4 cell count 
(p=0.881) nor median log viral load (p=0.490) differed between LTFU and those 
who survived. However, when comparing the number of patients with CD4 cell 
counts at different levels, there were significant differences between those L TFU 
and those retained. The proportions of those L TFU vs those who survived in the 
programme with CD4 cell counts <50, 51-100, 101-150 and >150 cells/µL 
respectively were 30% vs 25%, 18% vs 21 %, 18% vs 22% and 34% vs 32% 
(p=0.051). Over half of those LTFU (66%) and those who survived (53%) earned 
no monthly income (p=0.004). 
5.4.6.1 Crude association between baseline characteristics and loss-to-follow-
up: onHAART 
Table 11 shows the crude association between baseline characteristics and 




HAART (HR 1.30, 95% CI, 0.92-1.84; p=0.140). A one-year increase in age was 
associated with a 2% reduction in the risk ofL TFU (HR 0.98, 95% CT, 0.96-1 .00 ; 
p=0.050). The risk ofLTFU reduced with increasing CD4 cell count at entry 
(p=0.063). WHO stage at entry was not associated with the hazard of being LTFU 
on HAART (p=0.630), nor was log viral load (p=0.840). There was a highly 
significant dose response with monthly income (p=0.003). There was a 51% 
reduction in the risk of being LTFU for those earning Rl-R700/month compared 
with those earning nothing (HR 0.49, 95% CT, 0.26-0.91 ). This association was 
attenuated when comparing those earning over R700/month with those earning 
nothing (HR 0.55, 95% Cl, 0.37-0.83). 
Table 11: Crude association between baseline characteristics and risk of 
loss-to follow-up: on HAART 
( ·11anu:tl•ristic IJR 95'1., Cl p-, alue 
Gender 
Female 1.00 
Male 1.30 0.92-1.84 0.140 
Age 0.98 0.96-1.00 0.050 
CD4 cell count (cells/µL) 0.063 
<50 1.00 
51-100 0.59 (0.36-0.98) 
101-150 0.61 (0.37-1.02) 
>150 0.96 (0.63-1.45) 
WHO stage at entry 0.630 
I&Il 1.00 
III 0.82 (0.55-1.23) 
IV 0.85 (0.52-1.38) 
HIV RNA level, log 10 0.840 
copies/ml 
<= 5 Log 1.00 
> 5 Log 1.04 (0.73-1.46) 
Monthly income 0.003 
No income 1.00 
Rl-R700 0.49 (0.26-0.91) 
>R700 0.55 (0.37-0.83) 
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5.4. 6.2 Adjusted effect of male gender on LTFU in the period on HAART 
Proportional hazards models were used to assess the adjusted effect of male 
gender on the risk of being LTFU (Table 12). After adjustment for age, the hazard 
ratio for male gender was inflated from 1.30 (95% CI, 0.92-1.84) to 1.49 (95% CI, 
1. 03-2.14 ). After adjustment for age and monthly income, this association was 
reduced to 1.38 (95% CT, 0.94-2.01). Inclusion ofCD4 cell count in the model 
reduced the association further to 1.34 (95% CI, 0.91-1.96). 

















5.5 Results/or total cohort 
5.5.1 Enrolment &follow-up: total cohort 
1.0 
1.38 0.94-2.01 
0.98 0.95-1 .00 
1.0 1.0 
0.51 0.27-0.95 0.51 (0.27-0.96 





The total cohort includes 2843 HAART-nai:ve adults who entered the 
programme. At the end of one year's treatment, 1010 (36%) individuals had been 
censored and 1833 (64%) were still on HAART. Of those censored, 285 died and 
349 had HAART pennanently deferred. A total of 70 individuals were transferred 
to another facility and 137 were L TFU. At the time of censoring, 169 individuals 
were awaiting treatment. The total duration of follow-up time was 2102 person-
years. Females contributed 1437 person-years to follow-up time, and males 665 
person-years. The median duration of follow-up was 326 person-days (IQR, 95-
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395). Among females, the median follow-up time was 358 person-days (IQR, 
103-398). Among males, the median follow-up time was 267 person-days (TQR, 
90-394). 
5.5.2 Mortality: total cohort 
Table 13 compares baseline characteristics between those who died in the 
total cohort and those who were alive and were not transferred or L TFU to 
another facility after one year on HA.ART. It also compares characteristics of 
those who were LTFU vs those still alive on HA.ART. Overall, 285 (10%) people 
died. Of these, 166 (58%) were female (p=0.001). The incidence rate was 
13.6/100 person-years, with a marked gender difference. The incidence rate was 
lower among women than men (11 .5/100 person-years vs 17.9/100 person-years, 
p<0.001). 
On average, those who died were older than those who survived in the 
programme (34 vs 33, p=0.003). They had lower median CD4 cell counts than 
survivors (51 vs 106 cells/µL, p<0.001). Median log viral loads were higher 
among those who died than those who did not (5 .16 vs 4.81 , p<0.001). Those 
classified WHO stage I & TT, ITT or TV among those who died and those who 
survived were respectively 6% vs 24%, 51 % vs 55% and 43% vs 22 (p<0.001 ). 
Most of the individuals who died and over half of those who survived ( 62% vs 
52%) earned no monthly income (p=0.004). Table 14 shows the comparative 
survival proportions of the total cohort. 
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Table 13: Baseline characteristics by mortality and loss-to-follow-up: total 
cohort 
\lhe on p- p-
( haracteristic 11\ -\1{1' Deaths , aluc 
/ , 
I . IH ,alue 
-
Female, n (%) 1253 166 87 
(68%) (58%) 0.001 (64%) 0.240 
age, median (y) (IQR) 33 34 31 
(28-38) (29-41) 0.003 (26-37) 0.037 
CD4 cell count (cells/µL), 106 51 114 
median (IQR) (55-159) (16-111) <0.001 (39.5-170) 0.880 
CD4 cell count (cells/µL), n f/o) <0.001 0.051 
<50 388 127 41 
(23%) (50%) (30%) 
51-100 399 52 24 
(24%) (20%) (18%) 
101-150 393 37 24 
(24%) (15%) (18%) 
>150 485 38 47 
(29%) (15%) (34%) 
WHO stage at entry, n (%) <0.001 0.879 
I & II 436 17 35 
(24%) (6%) (25%) 
III 999 144 72 
(55%) (51%) (53%) 
IV 396 124 30 
(22%) (43%) (22%) 
mv RNA level, logJO copies/ml, 4.81 5.16 4.84 
median (IQR) ( 4.39-5 .24) ( 4.65-5.55) <0.001 (4.35-5.4) 0.490 
HIV RNA level, log10 copies/ml <0.001 0.817 
<= 5 Log 1256 93 81 
(61%) (43%) (60%) 
> 5 Log 797 123 54 
(39%) (57%) (40%) 
Monthly income, n (%) 0.004 0.004 
No income 788 157 86 
(52%) (62%) (67%) 
Rl-R700 205 29 11 
(13%) (12%) (8%) 
>R700 205 65 32 
(13%) (26%) (25%) 
6 p-value for comparison between those who died and those alive on HAART 
7 p-value for comparison between those who were L TFU and those known to be alive on HAART 
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Table 14: Kaplan-Meier survival estimates: men and women: total cohort 
l'imr 
(da~s) Females \I ales 
0 1.000 1.000 
30 0.981 0.970 
60 0.964 0.937 
90 0.945 0.915 
120 0.933 0.907 
150 0.925 0.887 
180 0.919 0.881 
210 0.915 0.875 
240 0.913 0.868 
270 0.908 0.863 
300 0.903 0.861 
330 0.899 0.855 
360 0.897 0.853 
390 0.893 0.853 
5.5.3 Crude association between baseline characteristics and mortality: total 
cohort 
Table 15 shows the crude association between baseline characteristics and 
the risk of death in the total cohort. Between entry into the programme and the 
end of a year's therapy, male gender increased the risk of death by 49% (HR 1.49, 
95% CI, 1.17-1.88; p=0.001 ). This is confirmed in the Kaplan-Meier survival 
curves (Figure 5). Older people were more at risk than younger (HR for a one-
year increase in age, 1.02, 95% CT, 1.01-1 .03 ; p<0.001 ). The risk of death was 
lower for those with higher CD4 cell counts at entry than those with lower CD4 
cell counts (HR 0.99, 95% CI, 0.99-0.99; p<0.001). This benefit was most marked 
among those with CD4 cell counts above 150 cells/µL (HR 0.24, 95% CI, 0.17-
0.34; p<0.001). Compared with those classified WHO stage I & II at entry, there 
was a greater than three-fold increase in risk for those in WHO stage III (HR 3.60, 
95% CT, 2.18-5.96). This strengthened to a nearly eight-fold increase in risk for 
individuals in WHO stage IV (HR 7.60, 95% CI, 4.55-12.55; p<0.001). For every 
one-log increase in HIV RNA level, there was a doubling in hazard (HR 1.98, 
95% CI, 1.52-2.60; p<0.001). Increased income was associated with a reduction in 
risk. Those earning above R700/month had a 37% reduction in risk compared 
with those earning nothing (HR 0.63, 95% CI, 0.47-0.85; p=0.006). 
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Table 15: Crude association between baseline characteristics and risk of 
mortality: total cohort 
p-
( hantl'tt'ristil' IIR 9='';;, Cl ,alue 
Gender 
Female 1.0 
Male 1.49 (1.17-1.88) 0.001 
Age l.02 (1 .01-1.04) <0.001 
CD4 cell count (cells/µL) 0.99 (0.99-0.99) <0.001 
CD4 cell count (cells/µL) <0.001 
<50 1.0 
51-100 0.44 (0.32-0.61) 
101-150 0.32 (0.22-0.46) 
>150 0.24 (0.17-0.34) 
WHO stage at entry <0.001 
I & II 1.0 
ill 3.60 (2.18-5.96) 
IV 7.56 ( 4.55-12.55) 
IDV RNA level, log10 <0.001 
copies/ml 
<= 5 Log 1.0 
> 5 Log 1.98 (1 .52-2.60) 
Monthly income 0.006 
No income 1.0 
RI-R700 0.73 (0.49-1 .09) 
>R700 0.63 (0.47-0.85) 
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5.5.4 Adjusted effect of male gender on the risk of mortality: total cohort 
Proportional hazards models were used to assess the adjusted effect of 
male gender on the risk of mortality in the total cohort (Table 16). The hazard 
ratio for male gender was reduced from 1.49 (95% CI, 1.17-1.88) to 1.30 (95% 
CI, 1.01-1 . 62) after adjustment for WHO stage at entry. It was further reduced to 
1.19 (95% CI, 0.93-1.50) after adjusting for WHO stage and age. Adjusted for 
WHO stage, age and CD4 cell count at entry, males had a 15% higher risk of 
death than women in the total cohQrt (HR 1.15, 95% CI, 0.93-1.50). 
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Table 16: Adjusted effect of male gender on risk of mortality: total cohort 
Female 
Male 
WHO stage at 
ent 











1.49 1.30 1.01-1.62 
1.0 
3.50 2.11-5.79 
7.20 ( 4.30-12.00) 




3.40 2.06-5.64 2.80 1.60-4.90 
5.26 (2.98-9.29) 





In the total cohort, degree of disease progression appeared to mediate the 
association between gender and death. Utilising the Sobel test, there was evidence 
to suggest that both CD4 (p=0.035) and WHO stage at entry (p<0.001) 
independently mediated the association between gender and death in the total 
cohort. Table 16 shows the marked attenuation between the crude and adjusted 
hazard ratios, amounting to a 34% reduction in the log hazard for death 
(comparing gender coefficients from models 1 and 4). 
5. 5. 6 Loss-to-follow-up: total cohort 
Table 13 (pg 57) also compares baseline characteristics of those LTFU with 
those who were still on treatment after one year. Of the patients who entered the 
programme, 137 (4.8%) were LTFU one year after starting therapy. Of these, 87 
(64%) were female. There was no significant ditlerence in gender distribution 
between those LTFU and those who were still on HAART (p=0.240). The median 
age was slightly lower among those LTFU than those still on therapy (31 vs 33, 
p=0.037). Neither median CD4 cell count (p=0.880) nor median log viral load 
(p=0.490) differed significantly between those L TFU and those who were retained 
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on HAART. However, when comparing the numbers of patients with CD4 cell 
counts at different levels, there were significant differences between groups. The 
proportions of those LTFU vs those who survived in the programme with CD4 
cell counts <50, 51-100, 101-150 and > 150 cells/µL respectively were 30% vs 
23%, 18% vs 24%, 18% vs 24%, and 34% vs 29% (p=0.051). Overall, 86 (67%) 
of those LTFU and 788 (52%) of the survivors earned no monthly income 
(p=0.004). 
5.5. 7 Crude association between baseline characteristics and loss-to-follow-
up: total cohort 
Table 17 shows the crude association between baseline characteristics and 
loss-to-follow-up in the total cohort. 
Table 17: Crude association between baseline characteristics and loss-to-
follow-up: total cohort 
( ·11anu:teristir Ill{ 9S'X, Cl p-, alue 
Gender 
Female 1.0 
Male 1.26 (0.89-1.78) 0.194 
Age 0.98 (0.96-1.00) 0.056 
CD4 cell count 1.00 (1.00-1.00) 0.582 
(cells/µL) 
CD4 cell count 0.101 
(cells/u.L) 
<50 1.0 
51-100 0.60 (0.36-0.99) 
101-150 0.60 (0.37-1.00) 
>150 0.87 (0.57-1.33) 
WHO stage at entry 0.714 
I & II 1.0 
III 0.85 (0.56-1.27) 
IV 0.87 (0.53-1.41) 
HIV RNA level, log10 
<= 5 Log 1.0 
>5Log 1.02 (0 . 72-1.44) 0.916 
Monthly income 0.002 
No income 1.0 
Rl-R700 0.48 (0.25-0.89) 
>R700 0.54 (0.36-0.80) 
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Between programme entry and the end of48 weeks ofHAART, men were at a 
slightly increased risk of being L TFU (HR 1.26, 95% CT, 0.89-1 .78; p=0.194). 
There was a minimal reduction in the risk of L TFU with increasing age (HR for a 
one-year increase in age, 0.98, 95% CI, 0.96-1.00; p=0.056). When CD4 count 
was used as a continuous variable, it did not appear to impact on L TFU (p=O .101 ). 
However, when included as a categorical variable, it seemed that those who 
enrolled with lowest CD4 cell counts were less likely to be L TFU, but this 
protection was reduced for those with CD4 cell counts > 150. Neither WHO stage 
(p=0.714) nor viral load (p=0.916) impacted on the risk ofLTFU. Income had the 
t,rreatest effect on the risk ofLTFU (p=0.002). There was a 52% reduction in the 
risk of L TFU among those earning up to R 700/month compared with those with 
no income (HR 0.48, 95% CI, 0.25-0.89). 
5.5.8 Adjusted effect of male gender on risk of loss-to-follow-up: total cohort 
Proportional hazards models were used to assess the adjusted effect of 
male gender on the risk of being L TFU in the total cohort (Table 18). Adjustment 
for age increased the risk for men compared with women (HR 1.43, 95% CI, 0.99-
2.06). Further adjustment for monthly income reduced the effect slightly (HR 
1.35, 95% CI, 0.92-1.97). Men were 35% more likely to be LTFU at 48 weeks 
than women. 
Table 18: Adjusted effect of male gender on risk of loss-to-follow-up: total 
cohort 
Gender 
Female 1.0 1.0 1.0 
Male 1.26 0.89-1.78 1.43 0.99-2.06 1.35 0.92-1.97 
A e 0.97 0.95-0.99 0.98 0.96-1.00 
Month! income 
RO 1.0 
Rl-R700 0.49 0.26-0. 93 
>R700 0.55 (0.37-0.83) 
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5. 6 Clinical outcomes at 48 weeks 
5. 6.1 Viral load at 48 weeks 
Viral load <50 copies/ml was regarded as viral suppression. Viral load 
measurements at 48 weeks were available for a total of 1012 patients, 824 (81 % ) 
of whom were female. There was no significant gender difference between the 
proportions achieving undetectable viral loads at 48 weeks (p=0.913). 
5.6.1.1 Crude association between baseline characteristics and viral 
suppression at 48 weeks 
Table 19 shows the crude association between baseline characteristics and 
viral suppression at 48 weeks. Only age is significantly associated with the 
outcome (OR 1.04, 95% Cl, 1.02-1.06~ p=0.001). 
Table 19: Crude association between baseline characteristics and viral 
suppression at 48 weeks 
p-
< harncteri,tk OH. 9:i'Y., Cl ,aim· 
Gender 
Female 1.0 
Male 1.02 (0.72-1.45) 0.913 
Age 1.04 (1.02-1.06) 0.001 
CD4 cell count (cells/µL) 0.388 
<50 1.0 
51-100 1.33 (0.84-2.10) 
101-150 0.96 (0.62-1.49) 
>150 1.27 (0.82-1.97) 
WHO stage at entry 0.243 
I&Il 1.0 
Ill 0.7 (0.46-1 .06) 
IV 0.81 (0.49-1.34) 
mv RNA level, log10 
copies/ml 
<= 5 log 1.0 
>Slog 0.93 (0.75-1.16) 0.545 
Monthly income 
No income 1.0 0.380 
Rl-R700 1.29 (0.85-1 . 98) 
>R700 1.21 (0.84-1.76) 
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5.6.1.2 Adjusted elf ect of male gender on viral suppression at 48 weeks 
Logistic regression models were used to assess the adjusted effect of male 
gender on viral suppression at 48 weeks (Table 20). In multivariate analysis, only 
age and WHO stage significantly influenced viral suppression. Adjustment for 
viral load at baseline and age reduced the odds ratio for male gender from 1. 03 
(95% CT, 0.72-1.46) to 0.85 (95% CT, 0.59-1 .24). Further adjustment for WHO 
stage at entry did not change this association (OR 0.86; 95% CI, 0.59-1.25). Men 
appeared to be 14% less likely to be virally suppressed at 48 weeks than womea 
Table 20: Adjusted effect of male gender on viral suppression at 48 weeks 
1.0 1.0 1.0 
1.03 0.85 0.59-1.24 
1.0 1.0 1.0 
0.93 0.91 0.73-1.14 0.95 0.76-1.18 
1.04 (1 .02-1.07) 1.04 (1.02-1.07) 
1.0 
0.66 (0.43-1.02 
IV 0.79 0.47-1.33 
5.6.2 CD4 cell count at 48 weeks 
CD4 measurements were available at 48 weeks for a total of 1 046 patients. 
I 
Of these, 751 (72%) were female . The mean CD4 cell count at 48 weeks for 
women was 296 cells/µL (range 54-724 ). Among men, the mean was 266 cells/µl 
(range 24-654). This difference was statistically significant (p<0.001). 
5.6.2.1 Crude association between baseline characteristics and CD4 cell count 
at48 weeks 
Modelling CD4 cell count at 48 weeks as a continuous variable (Table 21), 
on average men had 30.1 cells/µL less than women (95% CI, -48.8 - -11.5 ; 
p=0.002). CD4 cell count at baseline (p<0.001), age (p<0.001) and log viral load 
at entry (p=0.012) impacted on CD4 cell count at 48 weeks. Baseline 
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characteristics that did not significantly influence CD4 cell count at 48 weeks 
were WHO stage at entry (p=0.922) and monthly income (p=0.222). In addition, 
CD4 count at 48 weeks was modelled as two binary outcomes (CD4 cell count at 
48 weeks >200 vs <200; and CD4 >350 vs <350). Using logistic regression (not 
shown), men were 38% less likely than women to have a CD4 cell count >200 at 
48 weeks. They were 28% less likely than women to reach a CD4 cell count >350 
at 48 weeks. 
Table 21: Crude association between baseline characteristics and CD4 cell 
count at 48 weeks 
count cells/ <0.001 
51-100 11.3 -11.3 ; 33 .8 11.S 
101-150 57.4 (34.5; 80.4) 11.7 
> ]50 124.8 103.1; 146.5 11.1 
-3 .2 -4.2; -2.1 0.5 <0.001 
0.922 
3.3 (-13 .6; 20.3 8.7 
-0.8. (-21 .1; 19.5 10.4 
22.9 4.9; 40.1 8.9 0.012 
0.222 
-4.7 -26.9; 17.6 11.3 
>R700 -16.9 (-36.2; 2.3) 9.8 
5.6.2.2 Adjusted effect of male gender on CD4 cell count at 48 weeks 
Linear regression models were used to assess the adjusted effect of male 
gender on CD4 cell count at 48 weeks (Table 22). Adjusting for age ~nd CD4 cell 
count at baseline, the association between male gender and CD4 cell count was 
weakened. After adjustment for age and CD4, WHO stage and viral load at entry, 
men had lower CD4 cell counts at 48 weeks than women (-15 .3 cells/µL ; range -
33.2; 2.6). 
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Table 22: Adjusted effect of male gender on CD4 cell count at 48 weeks 
Male gender -23.4 -10.30 -12.7 -15 .3 
-40.8; -5.9 -28.20; 7.7 -30.7; 5.3 -33.2; 2.6 
CD4 cell count cells/ L 
51-100 9.1 13.0 17.5 20.8 
-13.4; 31 .7 -9.4; 35.3) -5 .0; 39.9 -1 .6; 43 .2 
101-150 54.9 57.7 65.7 74.8 
31 .9; 77.9 34.9; 80.4 42.4; 89.1 51 .5; 98.0 
>150 122.4 121.9 127.2 139.6 
(100.6; 144. l) (100.4; 143.4) (105 .S; 148.9) 117.6; 161.5) 
Age -2.6 -2.8 -2.9 
-3 .6; -1.6 -3 .8; -1 .8 -3 .9; -1.9 
WHO sta e at ent 
m 26.8 18.1 
6.9; 46.6 -1.6; 37.9) 
IV 34.8 28 .l 
10.5; 59.0 (4.1; 52.2 
HIV RNA level, log10 
co ies/ml 




This analysis explored gender differences in presentation and early survival 
in a South African community-based HAART programme. During the study 
period, 285 patients (10%) died. The pre-treatment mortality rates were high, but 
not different by gender (p=0.133). In contrast, the death rate was significantly 
lower among women than men in the period on treatment (7.9/100 person-years vs 
12.9/100 person-years, p=0.003). The mortality rate in the total cohort was also 
significantly higher among males than fomales (17.9/100 vs 11.5/100 person-
years, p<0.001). 
Overall, these results demonstrate a strong crude association between male 
gender and survival that was attenuated after adjustment for baseline markers of 
disease severity. In the pre-HAART period, there was a strong crude association 
between male gender and survival (HR 1.31, 95% CI, 0.93-1.86; p=0.131), which 
disappeared with adjustment for baseline characteristics (HR 1.01 , 95% CI, 0.67-
1.5 l). On HAART, the strong crude association (HR 1.57, 95% CI, 1.14-2.16; 
p=0.005) was attenuated after adjusting for the same characteristics (HR 1.19, 
95% CI, 0.88-1.97). In the total cohort, male gender increased the crude risk of 
death by 49% (HR 1.49; 95% CI, 1.17-1.88; p=0.001). This association was 
weakened after adjustment for WHO stage, age and CD4 cell count (HR 1.15, 
95% CI, 0.93-1.50). Degree of disease severity at programme entry appeared to 
mediate the effect of gender on survival. 
The analysis found that men were more likely to be L TFU on HAART in 
both univariate (crude HR 1.30, 95% CI, 0.92-1 .84; p=0.140) and multivariate 
analyses (HR 1.34, 95% CI, 0.91-1.96). 
In terms of virological outcomes, after adjustment for baseline 
characteristics, men appeared less likely than women to reach viral suppression at 
48 weeks (HR 0.86, 95% CI, 0.59-1.25). 
On average, women had higher CD4 cell counts at 48 weeks than men did 
(p<0.001). There was a crude association between male gender and lower CD4 
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cell count at 48 weeks. On average, men had 30.1 cells/µL less than women (95% 
CT, -48.8--11 .5~ p=0.002). After adjustment for disease parameters at baseline, 
men still had on average 15.3 cells/µL less than women (95% CI, -33.2 - 2.6). As 
women had significantly higher median CD4 cell counts at baseline than men 
(p=0.001), it seems likely that the association reflects disparities at baseline rather 
than a gender difference in clinical progression. 
6. 1 Strengths & limitations 
The strengths of this study are a well-maintained cohort with near complete 
ascertainment of outcomes, low levels ofLTFU, the inclusion of analysis time 
prior to HAAR T initiation, the large sample size and high quality baseline 
measurements. In addition, the study explores some of the underlying reasons 
why men are accessing HAART at later stages of disease progression than 
women. The major limitation of this analysis is the generalisability of results to 
other populations. 
6.1.1 Ascertainment of outcomes 
In low-income .countries, ascertainment of outcomes is generally 
constrained by a lack ofresources (Rosen et al. , 2007). Failure to ascertain 
outcomes accurately impacts on the validity of any measure of association that is 
estimated from ~ta. u: for instance, themajority of those who were recorded as 
L TFU had actually died, the measure of association would underestimate the true 
association between exposure and mortality (Joubert and Ehrlich, 2007). Any 
systematic difference between those who were retained in care and those who 
were lost to the programme might render the measure of association invalid. 
In the Gugulethu cohort, the low rate of L TFU reflects the fact that 
ascertainment of outcomes is fairly complete, due to the Sizophila adherence 
counsellors. In addition to supporting patients on treatment, the counsellors also 
undertake home visits. They are able to ascertain outcomes more accurately than 
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sites which rely on passive ascertainment. This is reflected in the low rate of 
L TFU. These findings are comparable with those from a large Canadian study 
(n= l219) with excellent ascertainment of outcomes. Hogg (Hogg et al. , 2001) 
used physician reports and record linkages with the registry of vital statistics to 
confirm outcomes. They found a non-significant crude association with male 
gender (RR 1.45, 95% CI, 0.70-3.02). After adjustment for baseline CD4, viral 
load and other factors, male gender did not predict survival. Good ascertainment 
of outcomes increases confidence in the findings of this analysis. 
6~1.2 Loss-to-follow-up 
A strength of this analysis is that this is a large, well-maintained cohort with 
low levels ofLTFU. The issue ofLTFU is highly topical with widescale HAART 
roll-out. Many developing countries are expanding their national programmes but 
lack resources to follow up patients who do not return once HAAR T is initiated. 
A recent systematic review of published papers on patient retention in Sub-
Saharan Africa found extremely high levels of LTFU (Rosen et al. , 2007). On 
average, the authors estimated that African HAART programmes retained about 
80% of patients at six months on HAART and 60% after two years on HAART. 
The main causes of loss to programme were reportedly LTFU (56%) and death 
(40%) (Rosen et al., 2007). Although the study did not analyse the data by gender, 
if there were a systematic gender difference between patients retained on HAAR T 
and those LTFU, this would result in selection bias. The true association between 
gender and survival would be unknown as the true outcome of the men and 
women lost to follow up would not be known (Joubert and Ehrlich, 2007). 
This is a crucial issue for programme monitoring and evaluation, as can be 
seen in the findings from a recent study in Malawi. The Malawian national 
HAAR T programme estimates that 9% of its patients on HAAR T are L TFU. In 
this study, researchers actively followed up a group of patients who were 
reportedly L TFU, to ascertain the true outcomes. They found that 50% ( 127) of 
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253- patients reported to be L TFU had actually died, most of them shortly after 
missing their last clinic visit (Yu et al. , 2007). 
Braitstein (Braitstein et al. , 2006) also highlighted the importance of LTFU 
in treatment programmes in developing countries. They suggest that with different 
assumptions of outcomes for those LTFU, the true mortality in their study might 
have been as high as 15% and not 6.4%, as estimated. Thi~ is a critical point, as 
there is enormous variability in definitions of L TFU. In a review of 33 cohorts, 
Rosen (Rosen et al ., 2007) found a wide range of definitions of LTFU including: 
missing two consecutive clinic visits; having no viral load results after treatment 
initiation; more than one month ( or two months/three months/four months) late 
for a visit or medication pickup or no visit in past one/two/three/four months; 
missing two consecutive clinic visits or no visit in the past three months. 
Comparing data with such widely varying definitions raises many analytical 
problems. The low rate of L TFU within this cohort strengthens confidence in the 
validity of the findings reported in this dissertation. 
6.1.3 Sample size 
A systematic review of earlier studies found little evidence of gender-
specific differences on HAART but suggested that the studies may have been 
underpowered to detect such differences (Nicastri et al. , 2005). The large sample 
size is a strength ofthis analysis. Although the Gugulethu site has been the subject 
of a fair amount of research previously, none of the previous studies has included 
as many study subjects. The most recent survival analyses on this cohort included 
I 2}5 adults, 927 of whom started-therapy (Lawn et al., 2006b). This analysis 
included more than double the number of participants (n=2843), 2196 of whom 
started HAAR T. 
The literature contains few other studies with comparable sample sizes, and 
most of these are collaborative analyses across different sites (Braitstein et al. , 
2006, Egger et al., 2002, Nicastri et al. , 2005). Multi-site analyses face a host of 
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analytical problems which may undermine-the validity of their findings . These 
include differing definitions of key variables (as with L TFU); the inclusion of 
different variables in crude and adjusted analyses; different time periods, drug 
regimens, study populations, sample sizes and- study methodologies. For these 
reasons, inferences from well-conducted, single-site studies with large sample 
sizes may provide stronger evidence of association. The only other analyses with 
larger sample sizes from a- single site are from Brazil (n=282 l) and Zambia 
(n= l 6198). Both studies reported similar results to this analysis: a crude 
association between male gender and survival on HAART which was attenuated 
after adjustment for stage of disease at baseline. The large sample size in a single 
site allows for precise estimates of effect and increases confidence in the findings 
of this analysis. 
6.1.4 Measurements 
Initially established. for research, the HCTC operates as a government 
HAART roll-out site as well as a research site. Clinic staff are trained and 
supported by staff from the Desmond Tutu HIV Centre at the University of Cape 
Town. The site is well-equipped. Staff have access to good laboratory services, 
some of them on-site, and a range of tests are performed at baseline and 
subsequent visits. As a result the cohort had high quality measures, which may 
explain some of the differences between this and previous studies. 
For example, the results of this analysis differed from the findings of a large 
study (n=1308) in Malawi investigating the effectiveness of a large-scale, 
simplified HAART programme (Ferradini et al. , 2006 ). The study population was 
similar to the Gugulethu cohort: poor, African and predominantly female. In this 
study, the association between male gender and death persisted even after 
adjustment for baseline factors including CD4 cell count (adjusted HR 1.63, -95% 
CT, 1.15-2.31 ). This may be partly due to the measurement of CD4 cell counts, 
which were initially measured manually and later semi-automatically. After a 
year, no systematic baseline CD4 cell count was done. In contrast, baseline CD4 
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cell counts were available for 85% of the Gugulethu patients and were performed 
at a quality-controlled laboratory on site. Without a fairly full set of valid baseline 
CD4 cell counts, it would be difficult to adjust adequately for the effect of CD4 on 
mortality. This may have· resulted in an over-estimation of effect in the Malawi 
study. 
Zachariah (Zachariah et al., 2006) provides some evidence to support this 
argument. Studying early deaths on HAART in the public sector, investigators 
had full baseline measurements for 1507 study participants, 66% of whom were 
female. Their estimated crude association between male gender and early death on 
treatment (OR 1.30) reduced when adjusted for baseline characteristics including 
CD4 cell count and WHO stage (adjusted OR, 1.20, 95% CI, 0.80-1.80). 
Similarly, the results of the Malawi study (Ferradini et al. , 2006) may have been 
undermined by the use of WHO stage as a proxy when CD4 was not available. 
The two measures were used interchangeably in the multivariate analysis. This 
may have artificially strengthened the apparent association between gender and 
death. 
Measurement issues may also have intluenced the results of a national study 
of survival among adult Brazilians with AIDS (Marins et al ., 2003). Researchers 
found that female gender predicted survival in crude (HR 1.15, p=0.022) as well 
as multivariate analyses (HR 1.15, p=0.053). As CD4 cell counts and viral load 
testing were unavailable for most of the study period, the study may not have 
adjusted adequately for baseline disease parameters. Instead researchers utilised a 
range of AIDS-defining criteria as proxies. It is possible that more adequate 
adjustment for stage of disease at baseline may have further weakened the 
estimate of the effect of gender on survival. 
6.1.5 Generalisability 
One major limitation of this analysis is generalisability. If one assumes that 
there is internal validity, and the findings reflect the true association between 
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gender and mortality after one year in an HAART programme, how may these 
findings apply to other populations? 
The HCTC is a unique clinic. Unlike general HIV clinics, it does not offer 
general HIV management to HIV-infected individuals who are in the early stages 
of HIV disease. Patients have already been tested, diagnosed and identified as 
requiring HAART. Consequently they may not be a representative sample of the 
general population of people with HIV who require HAART but have not yet been 
diagnosed. 
On the other hand, the study sample probably represents the population 
accessing HAART through the public health sector in South Africa as referrals in 
the public sector generally follow the same channels. Most women are tested and 
reforred for treatment during pregnancy via the programme to prevent mother-to--
child transmission, while men are diagnosed when presenting for TB or STI 
treatment. The findings may be generalisable to people accessing HAAR T via the 
public sector in South Africa and should have relevance to public health debates 
and decisions. 
It is not clear whether the results would be generalisable to other 
populations. However, congruence of study findings between this analysis and 
large studies of public HAART programmes in other African countries suggests 
that this may be the case. Future research should analyse and compare gender and 
survival in large cohorts in different settings. If significant differences are found 
between the results of this analysis and others in ditlerent settings, the reasons 
should be explored. This may provide invaluable data to inform HAAR T 
programmes in South Africa and elsewhere. The strong association between 
monthly income and the risk ofLTFU in a HAART programme also suggests the 
need for further research on the impact of socio-economic conditions in different 
settings. 
Finally, this analysis does not speak to long-term outcomes in an HAART 
programme. The Gugulethu programme is still in its infancy, as are many others 
in developing countries. Over the next few years, South Africa and other African 
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countries will face a host of new challenges in retaining patients on long-term 
treatment. With longer periods of follow-up, systematic gender differences in 
adherence, patient retention/LTFU), death and/or other outcomes may emerge, 
especially with many such health systems in crisis. 
Indeed, the strong crude association between gender and survival in this 
analysis suggests that over time, survival may in fact be different for men and 
women. While it is possible that gender disparities in survival are due to 
biological causes, it seems more likely that the underlying determinants may be 
sociological and/or structural. The crude association between male gender and the 
risk of being LTFU suggests that gender may impact on issues such as adherence. 
It will be important to undertake similar analyses over longer study periods in 
order to establish whether there are in fact gender differences in retention of 
patients on long-term treatment. If such differences are found, the reasons should 
be explored. 
6.2 lnterpretation 
6.2.1 Gender.& sun,ival 
With the widescale roll-out of HAART in developing countries, it is vital to 
understand whether and how gender affects survival. This analysis extends the 
findings of a recent collaborative study (Braitstein et al. , 2008a). Utilising 
baseline measurements from 29 sites including the Gugulethu clinic, the authors 
also found that women were starting HAAR T with less advanced HIV disease 
than men. In addition to this, the results of this analysis confirm that apparent 
gender disparities in survival on HAART may be due to the fact that men are only 
accessing HAAR T at later clinical stages of HIV than women. 
These findings are consistent with the results of other studies which found 
that after adjustment for stage of disease at programme entry, there was no 
significant association between gender and survival. Two other large studies in 
public -sector HA.ART programmes in Malawi and Zambia provide the most 
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relevant comparisons (Zachariah et al. , 2006, Stringer et al. , 2006). Probably the 
largest single cohort of patients on HAART (n=16198) is the Lusaka programme 
(Stringer et al. , 2006). The authors found that a crude association between male 
gender and survival (crude HR 1.40, 95% Cl, 1.20-1.60) was attenuated after 
adjustment for baseline measures of disease progression (HR 1.20, 95% CI, 0.90-
1.50). In Malawi, too, a crude association between male gender and mortality 
( crude OR 1.30) was weakened after adjustment for stage· of disease at 
presentation (adjusted OR 1.20, 95% CT, 0.80-1 .80, p=0.40). 
In developed countries, similar results have been found. Braitstein and 
colleagues (Braitstein et al. , 2006) undertook a large retrospective multicentre 
cohort study comparing patients in low- and high-income countries and found 
little difference between the settings. Females had less risk of death on HAART in 
low-income settings (crude HR 0.84, 95% CI, 0.58-1.22) and in high-income 
settings (crude HR 0 .85, 95% CI, 0.66-1.09). The ART-CC collaboration (Egger 
et al. , 2002) analysed data on 12574 HAART-na1ve adults in 13 cohort studies in 
Europe and North America. The study did not report crude associations but in 
multivariate analysis including baseline disease parameters, female gender did not 
increase the hazard of death (HR 1.05, 95% CT, 0.77-1.42). Our findings provide 
additional evidence to support the results of these large studies from low and 
high-income settings. 
In contrast to these findings, a large Brazilian retrospective review (Braga et 
al. , 2007) found that women were at a higher risk of mortality on HAAR T than 
men. The study found a crude association between female gender and mortality 
(HR 1.22, p=0.020), which strengthened after adjustment for age at HIV 
diagnosis, lowest CD4 count during follow-up, highest viral load, AIDS-defining 
illness before admission and during follow-up, and ART at end of follow-up 
( adjusted HR 1. 86, 95-% CI, 1.14-3. OJ} The authors found that women were 
significantly more likely to be diagnosed at a younger age and to receive HAART 
at earlier stages of disease. If women were healthier than men at the start of 
HAART, it seems unlikely that their survival would have been worse. It seems 
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more likely that the study detected an artefactual gender difference which would 
have disappeared or been attenuated with adjustment for disease parameters. 
There is overwhelming evidence that stage of HIV disease at programme 
entry is the main determinant of survival. For this reason, Lawn & Wood (Lawn 
and Wood, 2006) previously highlighted the need for earlier diagnosis and 
treatment. This dissertation confirms the finding of the recently published ART-
LINC paper (Braitstein et al. , 2008b) that there is a particular need for the earlier 
diagnosis and treatment of men in developing countries. 
6;2.2 Survival pre-HAART 
This is the first detailed analysis in a low-income country of survival by 
gender in the period before initiation of therapy. Most studies only report survival 
after initiation of HAART. In low-income countries, most patients presenting for 
treatment are already at advanced stages of disease progression due to stringent 
criteria for initiating HAART. Inclusion of data on patients in the period before 
starting HAART provides valuable insight into gender and pre-HAART mortality. 
It also provides some sense of the huge public health burden of HIV morbidity 
that remains hidden if people die before receiving treatment. 
In the pre-HAART period, there was a strong crude association between 
male sex and survival (HR 1.31, 95% CI, 0.93-1.86, p=0.131). The association 
disappeared· with adjustment for baseline characteristics including disease 
parameters (HR 1.01 , 95% CT, 0.67-1 .51 ). Tt is possible that due to the short 
period of follow-up prior to treatment (median duration 35 person-days; IQR, 26-
63 t there was limited statistical power to detect a gender difference. The effect of 
male gender might only have become discernible over a slightly longer period, 
and might have been detected in the early period on HAART. Results from other 
studies reporting male gender as a risk factor for early mortality on HAART 
(Ferradini et al. , 2006, Zachariah et al. , 2006) provide some evidence to support 
this. 
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63 Implications of this analysis 
This analysis found that mortality during the first year on HAART in this 
cohort is not independently associated with gender, but is mediated by stage of 
disease at entry into a programme. Although men appear to have poorer survival 
on HAAR T than women, this may be due to their later diagnosis and entry into an 
HAAR T programme. At present, South African men using the primary health 
services seem to be disadvantaged in access to HAAR T. Unless this issue is 
resolved, men may continue to have worse survival prospects than women in 
HAART programmes in South Africa, and possibly in other developing countries. 
The following section suggests some possible interventions to address this critical 
issue. 
6.3.1 Qualitative studies 
The results of this analysis highlight complex issues surrounding gender, 
HIV and health. However, the literature abounds with unsupported generalisations 
about men ' s health seeking behaviour. This begs the question: would men have 
different health seeking behaviour if the health services were more geared to their 
needs? In-depth qualitative studies in different settings are urgently needed to 
explore the real reasons why men make less use of public health services than 
women. 
6.3.2 Changes in national policy 
In order to ensure that the primary health care services in South Africa 
address the health needs of men, changes in national health policy are required. In 
particular, the HIV/ AIDS National Strategic Plan 2007-2011 should be revised 
urgently to address the existing gaps. In the light of these findings, the 
implementation plan should include a focus on how to diagnose and treat men at 
earlier stages of HIV disease. Men should be included in the section on 
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populations at higher risk. It might be appropriate to include a separate goal 
addressing the special needs of men, as the programme appears to have failed to 
do so to date. 
While it is vital to redress the gender imbalance in primary health care 
services, and specifically in access to HAART, this should not undermine existing 
health services for women, or obstruct their access to early diagnosis and 
treatment. Fortunately, with the existing strong focus on maternal and child 
health, particularly in HIV/ ATOS, it seems unlikely that this would happen . 
63.3 Men-friendly services 
Although policy changes create the framework for changes in health service 
delivery, these are long-term solutions. It is also essential to find short-term, 
achievable ways of increasing men's access to VCT and HAART. 
One solution would be to create preventive and reproductive health services 
that specifically target men. This could be done in partnership with non-
government organisations (NGOs), which may be better placed to initiate such 
projects. In Soweto, for example, the Imbizo Health Project set up two male-only 
health care facilities in 2005. The clinics provide health information in an 
environment that is supportive, confidential and private. Between November 2006 
and September 2007, a total of 4 758 males were tested, close to the target of 4 
950 (Whiting, 2008). The men who tested positive were referred to HAART sites, 
while those testing negative were referred to Imbizo post-test support services. 
Steven Whiting, Chief Executive Officer ofHIVSA, the founding organisation, 
argues that if there were public services targeting issues that men regard as 
important such as penile dysfunction and prostate cancer, men would flood into 
the services (Whiting, 2008). This would increase men's exposure to broader 
health services. Ultimately, increased interaction with health facilities is likely to 
increase the chances of men being diagnosed with HIV earlier, and consequently 
receiving earlier treatment. 
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Unfortunately such initiatives are subject to the same problems facing the 
beleaguered health services: a crisis in human resources, insufficient funding, and 
inexperienced management. They will require vision and commitment in order to 
succeed. Lessons may be learnt from the·experience of a male-only clinic in 
Khayelitsha, Cape Town. The clinic was established recently as an entry point for 
men to the health services, in response to a perception that the PHC clinics were 
women's clinics or baby clinics which did not cater for the health needs of men 
(De Azevedo, 2008) .8 The clinic is run collaboratively by provincial and city 
health authorities, a local NGO and an international NGO (Hope Worldwide and 
Medecins sans Frontieres). Accessibly located near the train station, the clinic is 
staffed by male nurses and counsellors and provides STI treatment and VCT. All 
patients are counselled and offered the opportunity to test for HIV. If they test 
positive~ they are referred to local clinics for management and HA.ART, as 
needed. Evaluation of services such as those offered by this clinic could inform 
similar projects elsewhere. 
6.3.4 Outreach programmes 
In addition to finding ways of bringing men .into existing health services, it 
may be necessary to take services to men. Engender Health, an international 
organisation active in international reproductive health issues, advocates reaching 
men in places where they congregate naturally. 
Providing mv testing facilities and equipment to measure CD4 cell counts 
in such venues could greatly increase men's access to diagnosis and early 
treatment. Imbizo Health currently offers VCT in shopping malls, one fixed site 
and mobile caravans. Nearly 500 men are tested a month, mostly at the mobile 
caravans which are situated close to where men gather socially or for work 
(Whiting, 2008). 
6 De Azevedo confirms that in fact, the PHC clinics only offer preventive/promotive health services for 
women and babies and offer no adult curative services except for TB and STis. 
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With government support, such organisations could·offer more accessible -
possibly even mobile - health services for men including HAART. For men who 
are working and cannot take off time without a doctor's note, these services 
should be offered outside working hours. VCT could also be otlered at 
workplaces, sporting or religious events, and social places such as shebeens 
(informal bars). 
In view of the public health relevance of this issue, a range of pilot studies 
should be undertaken to experiment with different innovative models for different 
settings. These could include: male-run clinics; separate rooms for men and 
women within the same clinic; separate days for men and women; after-hours 
clinics; mobile clinics taking male-targeted services to men where they gather 
socially or for work; and possibly mobile clinics offering HAART. Good 
monitoring and evaluation systems are central to such studies. Planning should 
focus on flexibility and moving quickly to build on successful initiatives and drop 
those that are not working. 
6. 3. 5 Changing attitudes 
It appears plausible that men's delayed diagnosis and treatment is due more 
to structural barriers than men's health seeking behaviour. However, if it is true 
that prevailing beliefs about masculinity prevent men from accessing general 
health services, these should be addressed. 
One way of changing stereotypes and behaviour is through national 
campaigns. The South African mass edutainment organisation Soul City utilises 
multimedia including print, television and radio, to promote important health 
messages. Such organisations could assist in formulating targeted, useful 
messages for men. These messages could, for example, highlight the benefits of 
early diagnosis and testing in terms of long-term prognosis. Similarly, instead of 
promoting condom use only to prevent HIV transmission, public messages could 
focus on the benefits of condoms for men living with HIV infection: not only in 
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protecting others from infection, but in preventing their own acquisition of STis, 
resistant virus and re-infection. This might help to shift the emphasis from men as 
perpetrators to men as partners in the epidemic, and emphasise the benefits of men 
knowing their status earlier. 
At an individual -level, a number of men' s organisations around the world 
are working to transform gender stereotypes. Most of these are small and still in 
their infancy, but could provide invaluable input on how to increase men' s access 
to HAART. One such initiative, Men as Partners, works to involve men in 
reproductive health. MAP collaborates with organizations and industries which 
are male-dominated, including the armed forces, mines, long distance transport 
and trade unions. Another organisation in India, Men in Maternity, actively 
involves men in maternity care. The organisation found significant changes in the 
family planning knowledge and behaviour of men who accompanied their wives to 
the clinics and participated actively in the intervention (Varkey et al ., 2004). An 
additional change to health care delivery in South Africa might be to create 
reproductive health services based on a family-focused care model, so that men could 
be offered HIV testing and access to treatment at the time of their partner' s 
pregnancy. 
Further qualitative research on the shared meanings of masculinity in 
different African settings is needed. This study' s finding that men are diagnosed 
and treated later than women is consistent with results from other large African 
HAART cohorts. This appears to be due to a complex, intertwined mix of 
behavioural, social and structural factors. It is important to recognise that there is 
no such entity as a stereotypical African man. On the contrary, there is huge 
diversity in gender norms and stereotypes which influence how men behave and 
how health services are structured. Further research on different constructs of 
masculinity in different contexts could shed light on this vital issue. 
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6.4 Summary 
In summary, there is mixed evidence to date on the association between 
gender and mortality among HIV-infected individuals starting HAART, especially 
in developing countries. This analysis found that in the pre-HAART period, a 
strong crude association between male gender and death might be explained by 
the stage of disease at programme entry. Thus, men are being diagnosed and 
initiating HAAR T at more advanced stages of disease progression than women, 
and consequently have worse survival prospects in the month between programme 
entry and initiation of therapy. 
On HAART, and in the total cohort, the marked increase in the risk of death 
among males was attenuated but not entirely accounted for by controlling for 
markers of disease stage and severity of immune suppression. This suggests that 
in these time periods, other factors such as adherence may also influence survival. 
The fact that males are at a higher risk of being LTFU at 48 weeks provides some 
evidence to support this argument. 
In the light of these findings, further research is needed on obstacles to male 
access to HAART. Changes to national policy are needed to fill existing gaps in 
health services. Male-friendly services including VCT and referral for HAART 
could become an entry point for men into the PHC system. This would facilitate 
the earlier diagnosis and treatment of men, and may improve their survival in a 
HAAR T programme. In addition, studies with longer follow-up periods are 
needed to identify other risk factors which may increase the risk of men being lost 
to programmes and/or being non-adherent to HAART. 
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8.2.3 Kaplan-Meier graphs: crude association between baseline 
characteristics and LTFU: on-HAART period 
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8.2.4 Kaplan-Meier graphs: c-rude association between baseline 
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Appendix 8.3 
Model diagnostics 
83.1 Cox's proportional ltazard regression models 
In the pre-HAART and total cohort models, overall and with respect to the 
individual covariates, the proportional hazards assumption was valid. In the on-
HAAR T model, the proportional hazards assumption was valid overall (p=O .123) 
and for all the individual variables except CD4 category 2 vs 1 (p=0.048). 
Although this is a minor violation of the proportional hazards assumption, as can 
also be seen in Figure 6 below, this is not a major concern as the focus of this 
analysis was the effect of gender on mortality. In addition, it is difficult to 
differentiate between a CD4 cell count below 50 cells/µLand a CD4 cell count 
below 100 cells/µL. As a further check, the models were run including each level 
of CD4 cell count separately, and this did not significantly change the effect of 
gender on mortality. As can be seen below, the proportional hazards assumption 
was not violated for gender. 
Figure 6: Tests of proportional hazards assumption for CD4 cell count and 
gender: on-HAART period 
N 
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Cox-Snell residuals were generated to check overall model fit. Kaplan-Meier 
curves were plotted with residuals (as the time variable) against death (Figure 7). 
For all three time periods, the line does not deviate much from the reference line, 
and the models provide a reasonably good fit for the data. 
Figure 7: Kaplan-Meier curves: Cox-Snell residuals vs mortality: pre-
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8.3.2 Logistic regression model 
The following assumptions were tested: 
• adequacy of the linear component 
• presence of outliers 
The linear predictor (Figure 8) appeared to be generally adequate. The two-way 
scatter (Figure 8) showed two groups fairly randomly scattered around zero. There 
did not appear to be any major outliers. The goodness-of-fit test produced a non-
significant result (p=0.236), showing that the predicted probability of viral 
suppression at 48 weeks did not differ substantially from the observed probability. 
Thus, this appears to be an acceptable predictive model. The logit transformation 
is appropriate for a binary response. The model appears to be valid. 
Figure 8: Diagnostics: logistic regression model 
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8.3.3 Linear regression nwdel 
The following assumptions were tested: 
• Normality of residuals 
• Collinearity 
The residuals appear to be normally distributed (Figure 9). Individual and global 
variance inflation factors (VIFs) were calculated. The individual VIFs were all 
< 10 and the mean VIF was 1.45. No collinearity was detected. The linear 
regression model appeared to be valid. 
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Appendix 8.4: HCTC data collection forms 
8.4.1 Guguletbu ARV site data capture: week-4s 
Date: -----
'· iniriab ·.- ·N.iunber· · DoB'':/1\ ; Gtit~er •· WHO .,:,·· Oate of-'" Comment: (Pregnant, 
· '· · '
1
· ,._' · ' · ·. : ·. · · '-· ,) · · ~hie:, ,, '. · ~ visit transfer~ non~naive) ; · 
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8.4.2 Guguletbu ARV site data capture: week-2s 
Date of meeting: ____ _ 
')ilit;ia.J.s ·. Numb~r · ··outcori:te ',: ./ .-. .: · ·»~g··requ'esttjt (E30,. .Comment: . (Pregn.ant, 
· ·: · : · · '·. ·· ( ord~r/defer)" ., N40' ~ttl,: '. . . ·. : transfer in, non-naive) 
Bring back to Desmond Tutu Centre: 
o All week O plastic folders (with carbon copies) 
o All on-treatment visit forms (carbon copies) 
o All change of treatment fonns. 
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8.4.3 Hannan Treatment Centre: patient background9 
Date: 
I Name: j Treatment no : 
Gender: M / F DOB: ... .. . .. ../. ...... .. ../. ..... ... ... 
1) Background History of ARV: Naive / Non-Nai've I PMTCT 
Has patient transferred in? Yes I No ART start date (if already on ARVs) ..... . ... .. / .. . ...... ./. ... . ..... 
Language spoken at home: 
.... .. . ... . .. ... ..... . .. . .. .... Is patient employed? Yes / No 
Level of education: 
Grade 1 / Sub A Grade 5 / Std 3 Grade 9 / Std 7 Tertiary Education 
Grade 2 / Sub B Grade 6 / Std 4 Grade 10 / Std 8 Unknown 
Grade 3 / Std 1 Grade 7 / Std 5 Grade I I / Std 9 Other 
Grade 4 / Std 2 Grade 8 / Std 6 Grade 12 / Matric None 
Date of last HIV(-) test: .. .. ... .. / .. . ..... ... / ... .. ... . Reason for test: illness TB 
Date of first HIV ( +) test: .. .. . ./. .. .... . ... / .. . . ...... . MTCT VCT Other 
Probable route of infection: Blood products Homosexual 
Intravenous Drug Use MTCT 
Heterosexual Unknown 
2) Disclosure of status: 
Partner or spouse Other family member Other household member Friend 
Employer Community Other None 
3) Clinical Information: 
Height: WHO Stage: Stage l Stage 2 
Weight: Stage 3 Stage 4 
Is patient pregnant: Yes / No If yes, LMP: .. ..... .. ./. .. .. .... ../. .. .... .... 
Bloods: Referral CD4 count: Date taken (CD4): ...... . .. / .... ....... / .... . ... .. . 
4)TB 
On TB therapy now: Yes I No How confirmed: Clinical 
Retreatment: Yes / No Smear Chest X-Ray 
Start Date: ... .... ..I. " .. ..... ./ ... " .... Other Culture 
TB site : 
9 The original data collection form used at baseline visits was unavailable electronically. It has 
been replaced by this patient background form, which collects similar information. 
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5) Cotrimoxazole: Start date: . .. .. ... . / .. ....... .. / ... ..... 
6) Previous HIV related illnesses: Date: 
.. 
Last pap smear (for women) 
..... .. . .I. ... ...... .I. ........ VDRL status: positive negative unknown 
Relationship status: Single With Partner Partner informed of HIV status: Yes I No 
Partner tested for HIV: Yes / No If yes, is pattner: Positive I Negative 
Children tested for HIV: Yes/ No If yes, specify age ofchild and status: 
Form completed by: 
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8.4.4 Gugulethu ARV site data capture: permanent outcomes 
Date: - ----
., " '(;.,) 
',' <' ',,,, 
Initials: Number: Date: Reason 
Initials Number Date of death Reason 
.. I>eath~ DN'.treatment . ;- .. , · · ..... . 
Initials Number Date of death Reason 
·_. L'I'F.tJtr1:ansfer.:ouf 
Initials Number Date Comment 
/Un'defers:· · 
. ,, 
Initials Number Date Comment 
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